



UNIVERSIDADE DE ÉVORA

ESCOLA DE CIÊNCIAS E TECNOLOGIA

DEPARTAMENTO DE QUÍMICA

**Isolation and molecular characterization of the
fatty acid synthase gene from an obese pig breed**

André Filipe Barreto Albuquerque

Supervisors:

Professor José Manuel Mota Ruivo Martins

Doctor Marta Sofia S. V. C. Ferreira Laranjo

Master course in Biochemistry

Dissertation

Évora, 2014

“Success consists of going from failure to failure without loss of enthusiasm.”

Winston Churchill

“You must be the change you wish to see in the world.”

Mahatma Gandhi

TABLE OF CONTENTS

TABLE OF CONTENTS	I
LIST OF ILLUSTRATIONS	III
LIST OF TABLES	V
ABBREVIATION LIST	VI
ACKNOWLEDGEMENTS	XIII
RESUMO	XIV
ABSTRACT	XV
I. INTRODUCTION	1
II. LITERATURE REVIEW	3
1. THE ALENTEJANO PIG - HISTORICAL AND LOCAL BACKGROUND	3
1.1. THE SWINE	3
1.2. PRODUCTION SYSTEM - THE INFLUENCE OF <i>MONTADO</i> AND <i>MONTANHEIRA</i>	4
2. SWINE-BASED RESEARCH	6
2.1. SWINE AS HUMAN BIOMEDICAL MODEL	6
2.2. SWINE BIOMEDICAL MODELS FOR OBESITY AND TYPE-2 DIABETES STUDIES –FATNESS GENETICS	8
2.3. POTENTIAL OF THE AL BREED	11
3. LIPID METABOLISM	11
3.1. INTRODUCTION TO LIPIDS – THE FATTY ACIDS	12
3.2. FATTY ACID CATABOLISM	14
3.3. DIETARY LIPID ABSORPTION	21
3.4. <i>DE NOVO</i> SYNTHESIS	23
3.5. BIOSYNTHESIS OF LONG-CHAIN SFAs, MUFAs AND PUFAs	30
4. FATTY ACID SYNTHASE	32
4.1. STRUCTURE AND ACTIVITY OF THE MAMMALIAN FAS COMPLEX	32
4.2. FAS GENE SEQUENCE AND POLYMORPHISMS	35

III. MATERIAL AND METHODS	36
1. SLAUGHTER CONDITIONS AND TISSUE COLLECTION	36
2. RNA EXTRACTION	36
3. COMPLEMENTARY DNA SYNTHESIS	36
4. cDNA AMPLIFICATION BY PCR	37
4.1. SEQUENCING STRATEGY	37
4.2. PRIMER DESIGN	38
4.3. PCR PROTOCOL OPTIMIZATION	39
5. ELECTROPHORESIS AND PURIFICATION OF PCR PRODUCTS	40
6. CLONING OF PCR PRODUCTS	41
6.1. CLONING VECTORS	42
6.2. PLASMID-INSERT LIGATION	44
6.3. TRANSFORMATION CONDITIONS	44
6.4. PLASMID DNA EXTRACTION	44
7. RESTRICTION ASSAY	44
8. DNA SEQUENCING AND ANALYSIS	45
9. RAPID AMPLIFICATION OF cDNA ENDS	45
9.1. 3' RACE APPROACH	46
IV. RESULTS	48
1. FRAGMENT AMPLIFICATION DETECTION	48
2. DETECTION OF THE PRODUCT AFTER RESTRICTION ASSAY	49
3. MOLECULAR CHARACTERIZATION OF THE SEQUENCED RESULTS	49
V. DISCUSSION	55
VI. CONCLUSIONS AND FUTURE PERSPECTIVES	58
REFERENCES	59
APPENDIX I – COMPLETE LIST OF TESTED PRIMERS	65
APPENDIX II – FULL ALIGNMENT PRESENTATION OF EACH SEQUENCED DNA PORTION	66

LIST OF ILLUSTRATIONS

ILLUSTRATION 1. INSULIN RESISTANCE INDUCED BY OBESITY MIGHT INVOLVE A COMPLEX NETWORK OF ENDOCRINE, INFLAMMATORY AND NEURONAL PATHWAYS.	9
ILLUSTRATION 2. THE STRUCTURE OF PALMITIC ACID OR PALMITATE (C16:0), ONE OF THE MOST COMMON FAS FOUND IN ANIMALS. CARBON COUNT STARTS FROM THE CARBOXYLIC GROUP (1), THE FIRST CARBON AFTER THE CARBOXYL CARBON IS CALLED A (2) WHILE THE NEXT IS KNOWN AS B (3) AND THE FOURTH AS Γ (4).	12
ILLUSTRATION 3. DISTINCT TYPES OF FATTY ACID-CONTAINING COMPOUNDS. A. THE STRUCTURE OF PHOSPHATIDYLCHOLINE (GLYCEROLPHOSPHATE-BASED LIPID), A PHOSPHOLIPID BASED ON A GLYCEROL BACKBONE ALONG WITH A PHOSPHATE GROUP, A CHOLINE GROUP AND TWO STEARIC ACIDS (C18:0); B. THE STRUCTURE OF A TRIACYLGLYCEROL COMPRISING A GLYCEROL AND THREE DISTINCT FA, FROM TOP TO BOTTOM: PALMITIC ACID (C16:0), OLEIC ACID (C18:1, Δ ⁹) AND ALPHA-LINOLENIC ACID (C18:3, Δ ^{9, 12, 15}); C. THE STRUCTURE OF THE ANIMAL WAX CERYL MYRISTATE, AN ESTER OF CERYL ALCOHOL AND MYRISTIC ACID (C14:0).	13
ILLUSTRATION 4. EXAMPLE OF FATTY ACIDS CLASSIFICATION USING THE DELTA NOMENCLATURE, FROM TOP TO BOTTOM: STEARATE (C18:0), TRANS-OLEATE (C18:1, Δ ⁹) AND CIS-OLEATE (C18:1, Δ ⁹).	14
ILLUSTRATION 5. HYDROLYSIS OF A TRIGLICERIDE INTO GLYCEROL AND FAS BY ADIPOCYTE LIPASES.	15
ILLUSTRATION 6. FORMATION OF ACYL ADENYLATE AND PYROPHOSPHATE IN THE FIRST REACTION OF THE FA ACTIVATION PROCESS.	16
ILLUSTRATION 7. THE SECOND ACTIVATION STEP COMPRISES THE FORMATION OF THE THIOESTER ACYL COA.	16
ILLUSTRATION 8. TRANSFER OF THE ACTIVATED ACYL INTO THE MITOCHONDRIAL MATRIX INVOLVES A PREVIOUS REACTION, ON THE OUTER MITOCHONDRIAL MEMBRANE, WITH CARNITINE FORMING ACYL CARNITINE.	17
ILLUSTRATION 9. SUMMARY OF THE ACYL GROUP TRANSPORTATION FROM CYTOSOL TO THE MITOCHONDRIAL MATRIX, A PROCESS MEDIATED VIA ACYL CARNITINE TRANSLOCASE.	17
ILLUSTRATION 10. B-OXIDATION INVOLVES 4 MAIN STEPS: OXIDATION, HYDRATION, OXIDATION AND THIOLYSIS.	18
ILLUSTRATION 11. AFTER B-OXIDATION, THE MAIN RESULTANT PRODUCT, ACETYL COA, ENTERS THE CITRIC ACID CYCLE FOR E ⁻ PRODUCTION THAT CAN BE TRANSPORTED VIA NADH AND FADH ₂ CARRIERS TO ENTER THE RESPIRATORY CHAIN FOR ATP SYNTHESIS.	19
ILLUSTRATION 12. THE FULL OXIDATION OF A MONOUNSATURATED FATTY ACID (MUFA) INVOLVES THE ACTION OF AN ISOMERASE TO CHANGE THE DOUBLE BOND LOCATION AND CONFIGURATION.	20
ILLUSTRATION 13. THE FULL OXIDATION OF A POLYUNSATURATED FATTY ACID INVOLVES THE ACTION OF AN ISOMERASE AND A REDUCTASE.	21
ILLUSTRATION 14. ABSORPTION OF DIETARY LIPIDS IN VERTEBRATES.	22
ILLUSTRATION 15. THE METABOLIC KEY ROLE PLAYED BY THE CIC PROVIDING A LINKAGE BETWEEN GLYCOLYSIS AND LIPOGENESIS. HMGCOA, 3-HYDROXY-3-METHYLGLUTARYL-COA; PYC, PYRUVATE CARRIER. (A) PYRUVATE DEHYDROGENASE, (B) CITRATE SYNTHASE, (C) ATP-CITRATE LYASE, (D) ACETYL-COA CARBOXYLASE, (E) FATTY ACID SYNTHASE, (F) 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE, (G) CYTOSOLIC MALATE DEHYDROGENASE, (H) MITOCHONDRIAL MALATE DEHYDROGENASE, (I) MALIC ENZYME.	24
ILLUSTRATION 16. THE FIRST STEP OF <i>DE NOVO</i> SYNTHESIS COMPRISES THE CARBOXYLATION OF ACETYL COA INTO MALONYL COA.	24

ILLUSTRATION 17. THE ACETYL COA CARBOXYLASE IS A THREE SUBUNIT POLYPEPTIDE THAT MEDIATES THE CARBOXYLATION OF ACETYL COA TO MALONYL COA.	25
ILLUSTRATION 18. REGULATION OF ACETYL COA CARBOXYLASE BY PHOSPHORYLATION/DEPHOSPHORILATION.	26
ILLUSTRATION 19. CONTROL ON THE FA BIOSYNTHESIS BY HORMONAL TRIGGERS AND OTHER SUBSTRATE FACTORS.	26
ILLUSTRATION 20. THE BASIC STEPS OF ONE CYCLE IN FA SYNTHESIS.	28
ILLUSTRATION 21. BIOSYNTHESIS OF MUFAS AND PUFAS DERIVE FROM PALMITATE SYNTHESIS WITH ACCESSORY ENZYME SYSTEMS. FAS SHADED PINK CANNOT BE PRODUCED BY MAMMALS AND HAVE TO BE INGESTED IN THE DIET.	30
ILLUSTRATION 22. THE DESATURATION OF A FA INVOLVES AN ELECTRON-TRANSPORT CHAIN.	31
ILLUSTRATION 23. FINAL CYCLIC REACTION IN PALMITATE SYNTHESIS MEDIATED BY FAS COMPLEX.	33
ILLUSTRATION 24. FRONT VIEW AND LINEAR ORGANIZATION SCHEMES OF THE MAMMALIAN FAS WITH RESPECTIVE CATALYTIC SITES COLORED.	33
ILLUSTRATION 25. THE BASIC STEPS IN POLYMERASE CHAIN REACTION; DNA DENATURATION, PRIMER ANNEALING AND EXTENSION.	37
ILLUSTRATION 26. PARTIAL SEQUENCING STRATEGY FOR THE FATTY ACID SYNTHASE GENE.	38
ILLUSTRATION 27. THE BASIC STEPS OF GENE CLONING.	41
ILLUSTRATION 28. PGEM [®] -T EASY VECTOR MAP AND POINTS OF INTEREST, NAMELY, AMP ^R AND LACZ GENE LOCATIONS.	42
ILLUSTRATION 29. PNZY28 MAP AND POINTS OF INTEREST, NAMELY, AMP AND LACZ GENE LOCATIONS.	43
ILLUSTRATION 30. OPERATION OF RESTRICTION ENZYMES – ECORI.	45
ILLUSTRATION 31. SUMMARY OF THE FASN 3' END AMPLIFICATION BY RACE.	46
ILLUSTRATION 32. EXAMPLES OF AMPLICONS GENERATED IN PCR ASSAYS USING DISTINCT PRIMERS OBSERVED BY 1% AGAROSE GEL ELECTROPHORESIS.	48
ILLUSTRATION 33. EXAMPLE OF AN INSERT RELEASE GEL AFTER THE RESTRICTION ASSAY.	49
ILLUSTRATION 34. NUCLEOTIDE SEQUENCE ALIGNMENT OF TOTAL SEQUENCED PRODUCT WITH SWINE FASN SEQUENCE NM_001099930.1.	53
ILLUSTRATION 35. PROTEIN SEQUENCE ALIGNMENT OF TOTAL SEQUENCED PRODUCT WITH SWINE FASN SEQUENCE NM_001099930.1.	54

LIST OF TABLES

TABLE 1. MAJOR ADVANTAGES OF A SWINE BIOMEDICAL MODEL.	7
TABLE 2. COMPLETE LIST OF PRIMERS USED IN FASN SEQUENCING ALONG WITH RESPECTIVE SEQUENCE, GENE LOCATION REGARDING TO SWINE FASN RECORD NM_001099930.1 ON GENBANK, ANNEALING TEMPERATURE AND AMPLIFIED PRODUCT SIZE.	38
TABLE 3. LIST OF PRIMERS USED FOR FASN 3' END SEQUENCING.	47
TABLE 4. CHARACTERIZATION OF THE IDENTIFIED POLYMORPHISMS. NOMENCLATURE OF MUTATIONS FOLLOWS OGINO ET AL. (2007).	55

ABBREVIATION LIST

7TM – Seven transmembrane receptors

ACC – Acetyl CoA carboxylase

ACP – Acyl carrier protein

AFW – Abdominal fat weight

AL – Alentejano

AMP – Adenosine monophosphate

AMPK – AMP-activated protein kinase

ATP – Adenosine triphosphate

BFT – Backfat thickness

BMI – Body mass index

bp – Base pairs

BSA – Bovine serum albumin

BW – Body weight

C – Carbon

°C – Celsius degree

ca. – *circa*

cAMP – Cyclic adenosine monophosphate

cds – Coding sequence

cDNA – Complementary deoxyribonucleic acid

CiC – Citrate carrier

CO₂ – Carbon dioxide

CoA – Coenzyme A

CVD – Cardiovascular disease

DH – Dehydratase

DMSO – Dimethyl sulfoxide

dNTPs – Deoxynucleotide Triphosphates

DNA – Deoxyribonucleic acid

EC – Enzyme classification number

E. coli – *Escherichia coli*

EDTA – Ethylenediaminetetraacetic acid

e.g. – *exempli gratia*

EGCG – Epigallocatechine-3-gallate

ER – Enoyl reductase

FA – Fatty acid

FAD – Flavin adenine dinucleotide

FADH₂ – Reduced form of flavin adenine dinucleotide

FAS – Fatty acid synthase

FASN – Fatty acid synthase gene

FFA – Free fatty acid

FW – Forward

g – Grams

g – Gravitational acceleration

h – Hour

H₂O – Water

HDL – High-density lipoprotein

kD – KiloDalton

KS – Ketoacyl synthase

KR – Ketoacyl reductase

IKK β – I κ B kinase- β

IL – Interleukin

IMF – Intramuscular fat

IPTG – Isopropyl-[beta]-D-thiogalactopyranoside

IRS – Insulin receptor substrate

IUBMB – International Union of Biochemistry and Molecular Biology

IUPAC – International Union of Pure and Applied Chemistry

JNK – Jun kinase

Kb – Kilobase

kDa – Kilodalton

kJ – Kilojoule

LDL – Low-density lipoprotein

LEPR – Leptin receptor gene

LPS – Lipopolysaccharide

M – Molar

MAT – Malonyl-acetyl transferase

MCP – Monocyte chemoattractant protein

min – Minute

mg – Milligrams

MJ – Megajoule

mL – Milliliters

mM – Millimolar

M-MLV – Moloney murine leukemia virus

mRNA – Messenger RNA

MUFA – Monounsaturated fatty acid

NAD⁺ – Oxidized form of nicotinamide adenine dinucleotide

NADH – Reduced form of nicotinamide adenine dinucleotide

NADPH - Reduced form of nicotinamide adenine dinucleotide phosphate

NCBI – National Center for Biotechnology Information

nm – Nanometer

nsSNP – Non-synonymous single nucleotide polymorphism

O₂ – Molecular oxygen

P – Pig

PCR – Polymerase chain reaction

PKC – Protein Kinase C

PUFA – Polyunsaturated fatty acid

QTL – Quantitative trait locus

rpm – Revolutions per minute

RNA – Ribonucleic acid

RNase – Ribonuclease

RT – Reverse transcription

RT-qPCR – Reverse transcription followed by quantitative polymerase chain reaction

RV – Reverse

s – Second

SCD – Stearoyl CoA desaturase

SFA – Saturated fatty acid

SNP – Single nucleotide polymorphism

SOCS – Suppressor of cytokine signaling proteins

SREBP1-c – Sterol regulatory element binding protein 1-c

SUB – Subcutaneous adipose tissue

TBE – Tris-Borate-EDTA

TE – Thioesterase

TLR – Toll-like receptor

TNF – Tumor necrosis factor

Tris – Tris (hydroxymethyl) aminomethane

U – Unit

UFA – Unsaturated fatty acid

UV – Ultraviolet

V – Volt

w/v – weight/volume

X-Gal – 5-Bromo-4-chloro-3-indolyl- β -D-galactopyranoside

μ L – Microliters

Nucleotide bases

A Adenine

T Thymine

G Guanine

C Cytosine

Amino acid nomenclature follows International Union of Pure and Applied Chemistry (IUPAC) and International Union of Biochemistry and Molecular Biology (IUBMB) recommendations (1984)

A Alanine

C Cysteine

D Aspartate

E Glutamate

F Phenylalanine

G Glycine

H Histidine

I Isoleucine

K Lysine

L Leucine

M	Methionine
N	Asparagine
P	Proline
Q	Glutamine
R	Arginine
S	Serine
T	Threonine
V	Valine
W	Tryptophan
Y	Tyrosine

This work is funded by FEDER Funds through the Operational Programme for Competitiveness Factors - COMPETE and National Funds through FCT - Foundation for Science and Technology under the Strategic Projects PEst-C/AGR/UI0115/2011 and PEst-OE/AGR/UI0115/2014.



ACKNOWLEDGEMENTS

First of all, I would like to thank ICAAM (Instituto de Ciências Agrárias e Ambientais Mediterrânicas) of the Universidade de Évora for providing the necessary conditions to make this work possible, particularly to professor Maria Ivone Clara for letting me stay at the Laboratório de Virologia Vegetal, where this project was carried out.

Thanks are due to *Associação Nacional de Criadores de Porco Alentejano* (ANCPA) for allowing the collection of samples from AL carcasses that enabled this work possible.

I would like to thank my supervisors, Professor José Manuel Martins and Doctor Marta Laranjo, for all their help, support, guidance, patience and availability.

I would also like to thank to Maria Mário and Luizeta Palma, technicians of Laboratório de Virologia Vegetal, for all support and assistance throughout this project.

Special thanks to Professor Rosário Félix and Doctor Carla Varanda for the warm welcoming in the lab, in which we spent so many days of scientific discussions, joy and helpful counseling, without them, this work would have never been possible. I could not forget to mention, all my friends and colleagues, particularly Helena Gaspar, Mônica Portella, Fernando Eliziário, Susana Santos, Mohamed Salem Zellama, Danielle Martinha, Mara Silva, Rodrigo Silva, Ana Paço, Miguel Landum, Margarida Santana, Clarisse Brígido, Ana Alexandre and to everyone else involved, my sincere and honest regards.

Finally, this work is dedicated to my family, particularly my brother and my mother, who, despite all, endured through the worst times alongside me during this critical stage of my life.

RESUMO

Isolamento e caracterização molecular do gene *fatty acid synthase* num porco obeso

O porco Alentejano é uma raça autóctone do sul de Portugal geneticamente idêntica ao porco Ibérico. Esta raça obesa é caracterizada por um crescimento lento e uma capacidade adipogénica precoce e elevada. A formação do tecido adiposo em suínos é obtida em 80% via síntese *de novo*, apesar de também poder ocorrer síntese independente de ácidos gordos intramusculares. O porco Alentejano apresenta a característica *genótipo “poupador” (thrifty genotype)*, responsável pelo elevado potencial e maior capacidade de deposição de tecido adiposo que outras raças comerciais magras.

O objetivo deste estudo foi determinar a sequência genética do enzima lipogénico *fatty acid synthase* (FAS) do tecido adiposo subcutâneo de um porco obeso de raça Alentejana. De acordo com a pesquisa feita, esta é a primeira publicação de uma sequência parcial deste gene em porcos Alentejanos. Através da clonagem de produtos de PCR, foram detetados três polimorfismos: c.6361C>T, c.6632C>A e c.6693C>T., sendo que os últimos dois conduzem a alterações no resíduo traduzido.

Palavras chave: Suíno; raça Alentejana; fatty acid synthase; ácidos gordos; lipogénese; deposição; adipócito; síntese *de novo*; gordura intramuscular; sequenciação.

ABSTRACT

The Alentejano (AL) pig is an autochthonous breed genetically similar to the Iberian pig. This obese breed is characterized by slow growth rates and precociously high lipogenic activity. *De novo* synthesis is responsible for about 80% of all fatty acid (FA) synthesis in swine adipose tissue, although independent intramuscular FA synthesis can also occur. The AL breed features the *thrifty genotype*, responsible for a higher potential and ability for fat deposition than other industrial lean breeds.

The aim of this study is to determine the gene sequence of the porcine fatty acid synthase (FAS) lipogenic enzyme of an obese AL pig in subcutaneous adipose tissue. To our knowledge this is the first publication of a partial sequence of this gene in AL pigs. Through cloning of polymerase chain reaction (PCR) assayed products three polymorphisms were detected: c.6361C>T, c.6632C>A and c.6693C>T, the latter two change the translated residue.

Key Words: Swine; Alentejano breed; lipogenesis; deposition; adipocyte; *de novo* synthesis; intramuscular fat; Fatty acid synthase; sequencing

I. INTRODUCTION

Sus scrofa domesticus, commonly known as domestic pig, is a eutherian mammal that has shared a natural bond with humans since the beginning of its domestication all across Eurasia around 10000 years ago up to modern breeding practices and biomedical models (Groenen et al., 2012).

Pigs are commonly raised for meat, which is the most important animal protein food source, and feed a majority of the global population. As an important meat source in a world with increasing and demanding food needs, particularly due to developing countries and exponential human population growth, this particular livestock species has increased its global population by 13 percent in the last two decades (FAO, 2013).

As a component of meat, fat, particularly saturated fat, is generally considered as deleterious to the health of the consumers, and is associated with higher chances on developing heart disease. Therefore animal feed strategies and processing technologies are nowadays increasingly used to alter meat composition to be more consistent with human dietary guidelines. Nevertheless, these strategies and techniques need to be based on the knowledge of the genetic potential and physiological characteristics of the animals to be efficient.

The perception of the adipose tissue being solely an energy storage organ has been extended to include an endocrine organ that plays a pivotal role in relation to energy homeostasis and metabolism. Apart from secreting free fatty acids, adipose tissue produces and releases numerous proteins and substances with autocrine, paracrine and endocrine functions.

The Alentejano (AL) pig, *Sus mediterraneus*, is an autochthonous breed, reared in the southern area of Portugal. This breed has been scarcely selected through centuries and due to its trend to fat deposition, is smaller in size and presents poorer meat yields than modern commercial breeds. This precocious and high trend of fat storage has been found not only in AL and Iberian pigs, but also in other animal species and even in humans, being named as “thrifty” genotype. In fact, the thrifty genotype is an adaptive mechanism to the environment allowing accommodation to cycles of feasting and famine (Neel, 1962). One intrinsic mechanism of the thrifty genotype has been recently associated in humans with a syndrome known as leptin resistance. Leptin resistance has been identified with disruptions of signal transduction processes at the level of leptin receptors with effects on food behavior and obesity (Lubis et al., 2008). Thus, leptin resistant individuals are obese genotypes with elevated leptin levels but unable to suppress feeding when food is in excess (Myers et al., 2008). In the Iberian pig a leptin receptor gene polymorphism has also been detected, with effects on food intake, body weight and fat deposition (Munoz et al., 2009; Ovilo et al., 2005).

Porcine genome sequencing it's of most importance because it provides a valuable feature for this livestock species progress, while enables continuous studying for multiple disease-causing variations extending the swine potential as a biomedical model. (Groenen et al., 2012)

This study's main goal is to sequence a lipogenic enzyme gene, fatty acid synthase (FAS), of an obese AL pig. Genotyping was performed in the most important tissue involved in the lipid metabolism, subcutaneous adipose tissue.

II. LITERATURE REVIEW

1. The Alentejano pig - Historical and Local Background

1.1. The Swine

The autochthonous pig breed Alentejano (AL) or *Black pig* is a traditionally raised breed that produces high quality meat products thanks to its particular production system and very particular genotypic features (Freitas et al., 2007; Lopez-Bote, 1998).

AL breed is reared in the southern region of Portugal and descends from *Sus scrofa mediterraneus* lineages, just as the genetically similar Iberian pig. Crosses between these two *Sus mediterraneus* descendants are common throughout the years. The Iberian pig term is accepted and used among many authors, to refer the several breeds existing in the Iberian Peninsula region (Martins et al., 2012; Nunes, 1993).

The Iberian Peninsula constitutes a strong historical and geographical unit that throughout history contributed to the formation of many local animal breeds, including the AL/Iberian pig. Nevertheless, there still is considerable genetic differentiation and relatively high genetic diversity found in Iberian breeds, most of them considered genetic resources (Canon et al., 2011; Matos, 2000; Nunes, 1993).

This Iberian swine branch presents, generally, several features: dark skin and hair color (if present); pointed snout; short and strong limbs. These morphological traits reflect the adaptation of the swine to the local conditions, particularly in terms of resistance to sunstroke and high temperatures (Fabuel et al., 2004; Nunes, 1993). Reproductive and zootechnical parameters are presented in several works (e.g. Freitas et al. (2006)).

Swine production can be divided into three distinct types depending on the final product: meat (e.g. Duroc, German Landrace, Pietrain); bacon (e.g. Danish Landrace, Tamworth) and fat (e.g. AL/Iberian, Gascon, Casertana). Meat-type pig breeds are characterized by high daily weight gains and are slaughtered with a low body fat content and constitute the main source of pork in developed countries, while fat-types have a lower BW gain and produce carcasses rich in fatness (Freitas et al., 2007; Switonski et al., 2010).

The AL is of smaller size and fatter, besides holding higher intramuscular fat (IMF) content than other Iberian breeds. This obese breed is characterized by slow growth rates

and precociously high lipogenic activity. Traditionally, these pigs are fed until they reach a body weight (BW) between 150 and 170 kg and 18-24 months of age, when they are ready for slaughter (Lopez-Bote, 1998; Martins et al., 2012; Nunes, 1993).

Unlike modern lean-type breeds, the AL is a local raised unselected breed with considerable genetic differentiation and poor productive traits. Nevertheless, until the second half of the 20th century, the AL pig breed was, economically, the most important Portuguese pig breed. Their meat, rich in IMF, is mainly used for the manufacture of high-quality dry-cured products. More recently, an increased interest on these products and in fresh meat from AL pigs has been observed among consumers, sustained by their intrinsic quality and healthiness (Freitas et al., 2007; Freitas et al., 2006; Gonzalez-Anover et al., 2010; Teixeira and Rodrigues, 2013) (see below).

Swine fatty acid (FA) synthesis is mainly through *de novo* synthesis (around 80% or more on adipogenic breeds) in adipose tissue with the possibility of independent intramuscular FA synthesis (Hood and Allen, 1973; Martins et al., 2012). Besides a higher content of fat, carcasses of AL and Iberian pigs generally present a higher content of oleic acid and (Estévez et al., 2006; Martins et al., 2012), consequently, a lower content of saturated fatty acids (SFA) commonly associated with the development of cardiovascular diseases (CVDs) (Estévez et al., 2006).

The production of AL and Iberian pigs is deeply rooted to the Mediterranean ecosystem. The contribution of this swine breed to the preservation and sustainability of its ecosystem is not common among the swine production industry (Lopez-Bote, 1998; Matos, 2000; Pugliese and Sirtori, 2012). In fact, local pig breeds and their production systems have been able to respond to the high criteria and expectations of modern society in regard to environment, animal welfare, and food quality and healthiness (Pugliese et al., 2013).

1.2. Production System - The Influence of *Montado* and *Montanha*

Alentejo, the southern region of Portugal where AL pig is reared, is full of extensive plains of poor, substantially degraded soils where livestock production represents an important local economic activity. The agro-silvo-pastoral system characteristic of this region is based on the *montado*. (Freitas et al., 2006).

The feed availability offered by the Portuguese *montado* is seasonal and also varies from year to year (Lopez-Bote, 1998; Nunes, 1993).

Traditionally, a diverse diet is supplied to pigs in extensive free-range conditions in long production cycles. Fattening periods during late October until February take full advantage of the *montado* landscape opposing the periods of scarcity where feed supplementation based on cereals/commercial diets might be required. The fattening

montanheira period explores local natural resources such as native pastures and *Quercus rotundifolia* and *Quercus suber* fruits (acorns), and is perfectly adapted to the AL extensive production. Acorns are low in protein, rich in the monounsaturated fatty acid (MUFA) oleate (C18:1) and pastures on polyunsaturated fatty acids (PUFA) linoleic (C18:2) and linolenic (C18:3) acids, besides fiber, protein and antioxidants such as alpha-tocopherol. Native pasture consumption also contributes for the detoxification due to the tannin content of acorns, while complementing the acorns low-protein content. In the traditional production systems, pigs are finished in the *montanheira*, where they are submitted to a quick and intense fattening period (Gonzalez-Anover et al., 2010; Matos, 2000; Nunes, 1993).

Modern explorations maintained the most dominant and interesting traits of the traditional production system, particularly, fattening pigs in *montanheira* associated with the exploration of reproductive sows. Nevertheless, there isn't a uniform production system since mating season, feed management, weight and age of slaughter varies among farms (Freitas et al., 2006).

More recently, an evolution in this production system has been verified, with the objective of a more intensified production. The feeding of pigs for example, is based on commercial MUFA-enriched diets having alpha-tocopherol supplementation up to 200 mg/kg in order to simulate the effects of the *montanheira* in the traditional free range feeding system (Daza et al., 2005). The growing interest on the semi-extensive camping system for swine management (requiring fewer workers) is another example (Matos, 2000).

Nowadays, pigs used to produce hams and dry-cured products are slaughtered at 150-170 kg BW and 14 to 24 months of age and are finished in *montanheira* (high quality products) or semi-extensive production systems (lower quality products). When sausages are the final product, pigs are slaughtered at 120-140 kg, and 14-20 months of age. Finally, for fresh meat, pigs are slaughtered at 90-100 kg and 8-14 months of age. These two final products are generally obtained from pigs reared in the semi-extensive and intensive production systems (Freitas et al., 2006).

Pork is one of the most produced and consumed meat-types in the world, despite the negative assumptions broadly made. The widespread opinion about the unhealthy effects of this meat is mainly related to its SFA and cholesterol content (FAO Food and Agricultural Organization of the United Nations., 2013a; Teixeira and Rodrigues, 2013; Wood et al., 2008).

Commercial lean-type pig breeds, developed to reduce pork total lipid content, have better productive traits when compared to AL and other unselected breeds. They are raised on intensive systems, using advanced technology which translates into an improvement in terms of carcass meat yield and manufacturing of low cost products. Nevertheless, animal products raised traditionally foster now more interest among consumers. This current interest might be associated with the characteristics of the extensive production systems that guarantee quality to the final product, increasing

consumer interest in organic and natural pig production. The high IMF content in AL/Iberian pork products is responsible for much appreciated organoleptic traits such as tenderness, juiciness and flavor (Gonzalez-Anover et al., 2010; Pugliese et al., 2013; Switonski et al., 2010).

AL and Iberian products represent an important part of traditional pork production and have significant commercial value. Furthermore, the distinctive FA profile of its meat, rich in unsaturated fatty acids (UFAs) and lower SFA content, contributes to an improved consumer approval of these products.

2. Swine-based research

2.1. Swine as Human Biomedical Model

The use of animal models for research of human diseases is a general practice that provides important information for development of prevention strategies and appropriate treatments. Better models rely on anatomic and physiological similarities to enable reliable extrapolations to humans.

Rodent subjects are widely adopted for human health studies. Nevertheless, rodent models occasionally fail to fully mimic human conditions, so an increasing need for animals closer to humans to further study diseases such as cystic fibrosis, diabetes or obesity, among others, is required (Cirera et al., 2014; Spurlock and Gabler, 2008; Walters et al., 2012).

In the last three decades, the adoption of pigs as human biomedical research model has broadly increased, particularly for general surgical models of most organs and systems, for cardiovascular research and in digestive system models, and more recently in transplantation and xenographic research through genetic engineering (Hamamdžić and Wilensky, 2013; Walters et al., 2012; Whyte and Prather, 2011).

Completion of the swine genome is currently simplifying and broadcasting the use of swine models in several research areas. For instance, it is now possible to search for single nucleotide polymorphisms (SNPs) of specific human disease genes and compare them to the ones existing in pigs. Through modern genomic modification techniques, swine gene functions can be altered, aiding the development of novel disease models based on transgenes on areas as diverse as cardiovascular disease, xenotransplantation and neurodegenerative diseases (Walters et al., 2012; Whyte and Prather, 2011).

The vast conserved homology shared by both, swine and human, genomes is one of the main features that support the extensive use of swine as biomedical models. Both species are omnivorous and their organs share similar functional features. Furthermore, resemblances in size, anatomy and physiology make the swine a suitable model for research in gene and cell therapy, xenograft and allograft procedures and other fields of regenerative medicine. Similar disease progression has allowed the possibility of a broad range of distinct biomedical swine research models. All-season breeding and large litter sizes provides great availability of individuals that hold short generation intervals (12 months) and gestation lengths (114 days), plus an early sexual maturity (5-8 months) and short lifespan (10-20 years). Handling pigs from the same litter, or cloned or transgenic pigs, eases genetic mapping. Choosing the right breed and age allows the execution of various surgical and non-surgical procedures generally used in human medicine, including catheterization, heart surgery, valve manipulation, endoscopy and broncho-alveolar lavages. In opposition, some of these procedures are found hard to practice in other animal models including rodents (Lunney, 2007; Meurens et al., 2012; Rothschild and Ruvinsky, 2011).

Swine also allow the possibility to perform time studies, image internal vessels and organs, and collect repeated peripheral samples and, at kill, detailed tissue samples. Access to well defined cell lines from different tissues eases gene expression and drug susceptibility testing, for example. Moreover, swine full genomic code is already available and its high sequence and chromosome structure homology with humans will provide a further improvement to its genomic and proteomic tools. Swine models are inexpensive and ethically more acceptable than primates and other animals since they are used for human feeding as well. Table 1 summarizes the general advantages of swine biomedical models (Lunney, 2007; Meurens et al., 2012).

Table 1. Major advantages of a swine biomedical model.

Adapted from Lunney (2007) and Meurens et al. (2012)

- Human sized - particularly miniature pigs
- Similar anatomy and physiology to humans
- Availability of individuals
- Advanced cloning and transgenic technology
- Availability of numerous well defined cell lines
- Similar disease progression (metabolic, infectious and across species diseases)
- Ability to perform various surgical procedures and of collecting multiple samples by choice
- Complete swine genome sequence availability with improving genomic and proteomic tools
- High sequence and chromosome structure homology with humans

2.2. Swine Biomedical Models for Obesity and type-2 Diabetes Studies – Fatness Genetics

Obesity is a chronic disease characterized by excessive body fat in tissues due to over accumulation of fat stores at the adipocyte level. In Humans, obesity is effectively diagnosed when body mass index (BMI) is superior to 30 kg m^{-2} . Obesity is a major health risk factor for a number of chronic diseases, including diabetes, cardiovascular diseases, and cancer. Among adults, worldwide prevalence of obesity is over 10% and prevalence of obesity and overweight ascend up to more than 30%. In Europe and Northern America these results reach 60 and 70% of the adult population, respectively. Despite these alarming results, trends are expected to climb even more in coming years (FAO Food and Agricultural Organization of the United Nations., 2013b; Spurlock and Gabler, 2008).

Biochemical mechanisms responsible for obesity haven't yet been fully identified and while rodent models have been extensively experimented for obesity research, their translational utility is less effective than pigs. This fact seems to be related with some differences at metabolic and physiological levels between rodents and humans. For example, several adipokines, such as adiponectin or resistin, cytokines secreted by the adipose tissue, appear to have different activities (Arner, 2005; Spurlock and Gabler, 2008). Furthermore, swine, as humans, are devoided of brown adipose tissue postnatally. This resemblance is very important since brown adipose tissue can induce heat production and therefore regulate energy balance (Harms and Seale, 2013; Spurlock and Gabler, 2008).

Several studies suggest that obesity is highly correlated with macrophage accumulation in adipose tissue. Activated macrophages secrete various cytokines and chemokines involved in systemic inflammation such as tumor necrosis factor (TNF)- α , interleukin (IL)-1, IL-6 and monocyte chemoattractant protein (MCP)-1, the later contributing to infiltration of adipose tissue with immunocytes (Harford et al., 2011; Spurlock and Gabler, 2008; Weisberg et al., 2003; Xu et al., 2003).

As obesity, type-2 diabetes is a major cardiovascular risk factor, namely for developing coronary heart disease (Haffner et al., 1998).

Chronic inflammation induced by obesity can develop insulin resistance. It is widely known that high plasma FA concentrations are closely related to obesity because expansion of the adipose tissue entails FA release from the adipocyte depots. Furthermore, obesity-associated changes induce alterations in the secretion patterns of adipokines that modulate insulin signaling (see illustration 1, path B). Recent in vitro studies have demonstrated that SFAs stimulate tissue inflammation the same way as bacterial lipopolysaccharides (LPS), through activation of toll-like receptors (TLR)-4 (illustration 1, path G) which indirectly promote cell inflammation with further production of pro-inflammatory TNF- α and IL-6 through the activation of protein kinases such as Protein Kinase C (PKC, EC 2.7.11.13), I κ B kinase- β (IKK β , EC 2.7.11.10), Jun kinase (JNK, EC 2.7.11.24) and the inhibitor of nuclear factor- κ B (NF- κ B, EC 2.7.11.10) (illustration 1,

path E). These kinases are responsible for the serine phosphorylation of insulin receptor substrates (IRS) that inhibits insulin signaling (illustration 1, path D). Moreover, the adipokine induced family proteins SOCS-3 conflict with IRS-1 and IRS-2 by phosphorylation or proteosomal degradation (illustration 1, path F). Main consequences to insulin sensitivity are an increased glucose synthesis in the hepatocyte, while on the myocyte the glucose uptake is decreased (Bjorntorp et al., 1969; Chait and Kim, 2010; Qatanani and Lazar, 2007; Spurlock and Gabler, 2008).




Illustration 1. Insulin resistance induced by obesity might involve a complex network of endocrine, inflammatory and neuronal pathways.

Another adipokine closely related to obesity and inflammation, in pigs as in humans, is adiponectin. Adiponectin is a protein secreted exclusively by adipose tissue that modulates lipid metabolism by inducing AMP-activated protein kinase, AMPK (EC 2.7.11.31), activity which deactivates acetyl CoA carboxylase, ACC (EC 6.4.1.2) and, consequently, suppresses carbohydrate transformation into lipid reserves by inhibiting *de novo* fatty acid synthesis. A small number of studies showed that lower concentrations of circulating adiponectin are found in obese and among insulin resistant subjects, suggesting anti-inflammatory effects. On the other hand, leptin is an adipocyte secreted hormone that regulates physiological functions in energy shortage periods and, when absent, leads to major metabolic disturbances due to increased insatiability. Adiponectin and leptin are found to be reciprocally regulated (Brennan and Mantzoros, 2006; Qatanani and Lazar, 2007; Spurlock and Gabler, 2008; Wu et al., 2003).

Anti-inflammatory effects by adiponectin have been reported in both swine and human adipose tissue. Production of pro-inflammatory cytokines as IL-6 and TNF by activated macrophages is suppressed by adiponectin. On the other hand, IL-6 and TNF

regulate adiponectin expression by inhibiting its mRNA expression (Spurlock and Gabler, 2008).

Further studies, using more swine subject models, might uncover more or confirm about the crucial role that these and other factors might have in inflammation, obesity and obesity-related diseases. These studies will include the search for gene mutations, polymorphisms and allele comparison in relevant genes, taking advantage of the recent availability of the full swine genome sequence and development of techniques such as SNP microarrays (Bruun et al., 2003; Spurlock and Gabler, 2008; Switonski et al., 2010; Wulster-Radcliffe et al., 2004; Yokota et al., 2000).

Evaluation of genetic predisposition through comparative genomic studies on obesity candidate genes and search for fatness quantitative trait loci (QTLs) are current fields of obesity research in expansion. All these obese swine traits have high polygenic background. To date, more than 100 loci have been identified and associated with obesity-related traits by genome-wide association studies (GWAS) as well as several candidate genes. Nevertheless, this approach is revealing to be rather limited since the individual expression value of current identified candidate genes is quite low when explaining fatness phenotypic traits. This is thought to be related with the high polygenic background involved in the determination of fatness traits, as well as the possibility of epistatic effects between potential genes (Cirera et al., 2014; Schook et al., 2005; Switonski et al., 2010).

Modern pig breeding has also found interest in studying swine genetic background in order to improve livestock production. Most important and studied swine fatness traits are backfat thickness (BFT), abdominal fat weight (AFW), IMF content and FA composition. BFT and AFW are related to fattening efficiency while IMF and FA composition affect quality meat traits and display nutritional value. IMF levels vary between breeds and muscle type. In *Longissimus dorsi*, for example, one of the most valuable muscles, the average IMF content in selected breeds is about 1.7%, while in AL/Iberian pigs this is much higher and may attain 6%. Furthermore, lean-type pig breeds are selected towards lower levels of BFT and growth of leaner tissues (Daza et al., 2006; Switonski et al., 2010).

Limitations occur when translating conclusions about porcine candidate genes to humans and vice-versa in fatness deposition. While studies of human obesity focus on BMI, traits studied in swine are concerned with different aspects of fatness which span candidate genes that may not prove to be as relevant for human obesity research. Nevertheless, particular animal models, such as the obese Ossabaw pig, are becoming increasingly valuable assets to understand the development of human obesity, obesity-induced insulin resistance and ultimately the metabolic syndrome and cardiovascular diseases. (Switonski et al., 2010)

2.3. Potential of the AL Breed

Several recent research studies about human obesity and development of metabolic syndrome have been done with Ossabaw pigs as models. For example, this breed can easily and efficiently simulate human atherosclerosis. This swine breed is exclusively found on Ossabaw Island (Georgia, USA) and features a thrifty genotype which drives it to feast in excess, easily become obese and develop all pathologies clustering metabolic syndrome such as obesity with severe visceral adipose expansion, primary insulin resistance, glucose intolerance, dyslipidemia and hypertension. Presence of three out of five of these symptoms is required to characterize metabolic syndrome in humans. Ossabaw swine can become overly obese even when fed with diets with no added fat but rich in carbohydrates. Recent studies suggest that these pigs are descendent from an Iberian branch which may explain their morphological and metabolic similarities (Brisbin and Sturek, 2009; Faris et al., 2012; Hamamdzcic and Wilensky, 2013; Spurlock and Gabler, 2008; Toedebusch et al., 2014).

Understanding of the pathophysiology of metabolic syndrome has been delayed by the lack of efficient human-like models. However, Ossabaw breed happens to be one of the best models for studying metabolic syndrome in humans due to the easiness in developing all its associated pathologies at once. As the Ossabaw strain, AL pigs hold high propensity for obesity, due to an adaptive thrifty genotype, including a great capacity to accumulate intramuscular and epidermal fat (Hamamdzcic and Wilensky, 2013).

Iberian pigs hold a polymorphism on the leptin receptor gene (LEPR) causing a condition commonly known as *leptin resistance*, characterized by failure in feeding suppression due to high concentrations of leptin found in obese individuals. This genetic feature results in implications at food intake, BW and fat deposition patterns, promoting obesity development (Munoz et al., 2009; Ovilo et al., 2005).

Recently, a study conducted by Torres-Rovira et al. (2012) concluded that within three months, Iberian sows with access to an *ad libitum* diet enriched with saturated fat, developed all five criteria associated to metabolic syndrome. This suggests that AL/Iberian pigs could be a valuable human model for further comprehension on mechanisms involved in obesity and its associated comorbidities.

3. Lipid Metabolism

This chapter will be focused in introducing mammalian lipids as important energy stores in adipose tissue, and their successive transformations, depending on the current metabolic needs.

3.1. Introduction to Lipids – The Fatty Acids

Lipids are a class of biomolecules that display a variety of distinct biological and structural functions. Lipids integrate cell membranes, carry fat soluble vitamins, and play vital roles as enzyme cofactors, hormones, and electron carriers, among others. Nevertheless, their main function lies in providing energy (Berg et al., 2012; Hussain et al., 2013; Lehninger et al., 2008).

Animals store energy mainly in the form of fat so that proteins don't have to be used, allowing them more important roles such as building and repairing tissues. In addition, storing calories as fat is more efficient than with the same mass of carbohydrates in the form of glycogen. Energy stores offer survival for long periods of food deprivation and its associated efficiency is thought to offer important advantages to animals during evolution (Lehninger et al., 2008; Semenkovich, 1997).

Animals store energy in the form of FAs, the simplest class of lipids. They contain a methyl group, a long hydrophobic hydrocarbon chain varying between 4 and 36 carbon atoms, and a terminal carboxylate group (illustration 2). FAs can be stored in excess amounts in the adipose tissue and oxidized in all tissues, particularly liver and muscle, acting as a major source of fuel to cells. In the form of phospholipids (mainly phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin), FAs form the backbone of cell membranes and contribute for their fluidity and functionality. FAs can also be found freely, circulating bound to albumin or integrated in triacylglycerols and waxes (Lehninger et al., 2008; Tvrzicka et al., 2011; Vance and Vance, 2008) (see illustration 3).




Illustration 2. The structure of palmitic acid or palmitate (C16:0), one of the most common FAs found in animals. Carbon count starts from the carboxylic group (1), the first carbon after the carboxyl carbon is called α (2) while the next is known as β (3) and the fourth as γ (4).




Illustration 3. Distinct types of fatty acid-containing compounds. **A.** The structure of phosphatidylcholine (glycerolphosphate-based lipid), a phospholipid based on a glycerol backbone along with a phosphate group, a choline group and two stearic acids (C18:0); **B.** The structure of a triacylglycerol comprising a glycerol and three distinct FA, from top to bottom: palmitic acid (C16:0), oleic acid (C18:1, Δ^9) and alpha-linolenic acid (C18:3, $\Delta^{9, 12, 15}$); **C.** The structure of the animal wax ceryl myristate, an ester of ceryl alcohol and myristic acid (C14:0).

Fatty acids can be defined as being saturated or unsaturated, depending on the absence or presence of double bonds between two carbon atoms in the aliphatic chain, respectively. Furthermore, UFAs display cis-trans isomerism, describing the orientation of the alkyl groups around the double bond. The trans isomer of a given FA can rarely be found in nature. Trans FAs can be obtained in dairy products or their meat and can also be produced by partial hydrogenation of fish and vegetable oils. Large dietary intakes of trans FAs are strongly correlated to increased levels of triacylglycerols and LDL (low-density lipoprotein) cholesterol and lower levels of HDL (high-density lipoprotein) on blood, conducting to a higher risk in developing cardiovascular diseases (Chilliard, 1993; Lehninger et al., 2008).

Delta (Δ) FA nomenclature is a simple mean of classification and identification of different FAs by specifying the chain length and number of double bonds, separated by a colon. In addition the number superscripted above the Δ represent the number of carbons from the carboxylic acid end to the first carbon in the double bond (Lehninger et al., 2008) (illustration 4). This simplified nomenclature, along with common names, will be recurrently used throughout this thesis.




Illustration 4. Example of fatty acids classification using the delta nomenclature, from top to bottom: stearate (C18:0), trans-oleate (C18:1, Δ⁹) and cis-oleate (C18:1, Δ⁹).

3.2. Fatty Acid Catabolism

Animal cells can obtain FAs from three distinct pathways: fats ingested in the diet, lipolysis of lipids stored in cells and *de novo* synthesis.

Triacylglycerols are formed by esterification of the three hydroxyl groups of glycerol by carboxyl groups of organic acids. They function as highly concentrated energy stores accumulated in cell depots, mainly in liver and adipose tissue. Their energy yield from complete oxidation is nearly 38 kJ g⁻¹ whereas from carbohydrates and proteins is 17 kJ g⁻¹. Such difference lies in the fact that FAs are much more reduced than carbohydrates or proteins (Berg et al., 2012).

Adipose tissue cells or adipocytes, are specialized cells that act as major site for triacylglycerol storage and synthesis. In mammals, adipose tissue can be found all over the body, particularly under the skin (subcutaneous) and surrounding internal organs (visceral). This tissue works mainly as an energy depot, where droplets of triacylglycerols tend to form large globules that can fill most of cell's volume. The surface of these droplets is covered with perilipins that restrict the access to the lipids (Berg et al., 2012).

Lipolysis and β-oxidation of free fatty acids (FFAs) is the main energy-yielding pathway for animal tissues. This process occurs in the mitochondria and is characterized by the degradation of FAs to generate acetyl-CoA. Access to the lipid energy reserves stored in adipose tissue involves three main stages: i) mobilization of FFAs; ii) activation and transport to the mitochondria; and iii) degradation into acetyl CoA (Berg et al., 2012; Lehninger et al., 2008).

3.2.1. Mobilization of Free Fatty Acids

The first step consists in isolating the FAs stored as triacylglycerols or mobilizing FFAs. For that, lipases of adipose tissue are activated to hydrolyze triacylglycerols into glycerol and FAs in a process also known as lipolysis (illustration 5).


Adipocyte lipases are activated by hormones such as epinephrine or glucagon. These hormones are responsible for the trigger of seven transmembrane (7TM) receptors that induce adenylate cyclase (EC 4.6.1.1) activity. Increased levels of cyclic adenosine monophosphate (AMP) stimulate protein kinase A (EC 2.7.11.11) activity which, afterwards, activates cytosol hormone-sensitive lipases (EC 3.1.1.79) and perilipins by phosphorylation (Berg et al., 2012; Lehninger et al., 2008).

Activated perilipins are the proteins responsible for: restructuring of the lipid droplet in a way that it's easier for lipases to access triacylglycerols; the release of a coactivator for the adipose triglyceride lipase (ATGL, EC 3.1.1.3). ATGL hydrolyzes a FA forming diacylglycerol in the process, while hormone-sensitive lipase removes a second FA. Monoacylglycerol lipase (EC 3.1.1.23) completes the mobilization producing a last FFA and glycerol (Berg et al., 2012).

Released FFAs are not soluble in blood, so they bind into serum albumin, which will carry them to the energy-requiring tissues. On the other hand, the glycerol is absorbed by the liver where it's transformed into glyceraldehyde 3-phosphate and can participate in either the glycolytic or gluconeogenic pathways (Berg et al., 2012).

3.2.2. Activation and Transport to the Mitochondria


Full animal FA oxidation occurs in the mitochondrial matrix. FA with chain lengths of 12 or fewer carbons do not need membrane transporters to enter in the mitochondria. Longer FFAs need to be activated and then carried by a carnitine based transport mechanism to reach the mitochondrial matrix (Lehninger et al., 2008).



Adapted from Berg et al. (2012)

Illustration 5. Hydrolysis of a triglyceride into glycerol and FAs by adipocyte lipases.


Activation occurs on the outer mitochondrial membrane where long-chain FFAs are linked to Coenzyme A (CoA) by a thioester bond, in a reaction catalyzed by acyl CoA synthetase (EC 6.2.1.3). This process is ATP-dependent and comprehends 2 steps. On the first one, the FA reacts with ATP forming acyl adenylate releasing pyrophosphate (illustration 6) (Berg et al., 2012; Lehninger et al., 2008).



Adapted from Berg et al. (2012)

Illustration 6. Formation of acyl adenylate and pyrophosphate in the first reaction of the FA activation process.

On the second step, the thiol group of CoA displaces AMP, conducting to the formation of the thioester acyl CoA (illustration 7).




Adapted from Berg et al. (2012)

Illustration 7. The second activation step comprises the formation of the thioester acyl CoA.

Both reactions are reversible and have an equilibrium constant close to 1. In order to pull these reactions in the forward direction, the pyrophosphate formed in the first reaction is rapidly hydrolyzed into two monophosphates by an inorganic pyrophosphatase (EC 3.6.1.1) (Berg et al., 2012; Lehninger et al., 2008).


FFAs are activated on the outer mitochondrial membrane, yet they are oxidized in the mitochondrial matrix. Their transfer across the mitochondrial membrane involves carnitine. The acyl group present in the activated long-chain FFAs binds to the hydroxyl group of carnitine to form acyl carnitine in a reaction catalyzed by carnitine acyltransferase I (EC 2.3.1.21) (Berg et al., 2012; Lehninger et al., 2008) (illustration 8).



Adapted from Berg et al. (2012)

Illustration 8. Transfer of the activated acyl into the mitochondrial matrix involves a previous reaction, on the outer mitochondrial membrane, with carnitine forming acyl carnitine.

Acyl carnitine translocase mediates the entrance of the acyl carnitine ester to the mitochondrial matrix. There, the acyl group is transferred from acyl carnitine to intramitochondrial CoA, in a reaction catalyzed by carnitine acyltransferase II (EC 2.3.1.21), releasing free carnitine. Carnitine can, then, return to the cytosolic side of the mitochondrial membrane through the translocase in exchange for acyl carnitine to balance the process (Berg et al., 2012) (illustration 9).



Adapted from Berg et al. (2012)

Illustration 9. Summary of the acyl group transportation from cytosol to the mitochondrial matrix, a process mediated via acyl carnitine translocase.

3.2.3. Fatty Acid Degradation – β -oxidation


Within the mitochondrial matrix, a four-step operation known as β -oxidation occurs. This cycling oxidation process takes place at the β carbon atom and includes a first oxidation by flavin adenine dinucleotide (FAD), hydration, oxidation by oxidized nicotinamide adenine dinucleotide (NAD^+) and thiolysis by CoA (illustration 10) (Berg et al., 2012).

In the first step, acyl CoA is oxidized to produce a double bond between carbon atoms 2 and 3 in an oxidation process also known as dehydrogenation that is catalyzed by acyl CoA dehydrogenase (EC 1.3.8.7). The lost hydrogen atoms reduce the electron carrier FAD to its reduced form FADH_2 (Berg et al., 2012; Lehninger et al., 2008).

The resultant product, $\text{trans-}\Delta^2$ -enoyl CoA, is then hydrated on the second step conducting to the formation of L-3-hydroxyacyl CoA in a reaction catalyzed by enoyl CoA hydratase (EC 4.2.1.17) (Berg et al., 2012; Lehninger et al., 2008).


The third step involves another oxidation reaction, which converts the hydroxyl group at C-3 into a keto apart from generating reduced nicotinamide adenine dinucleotide (NADH) from NAD^+ . This oxidation is specifically catalyzed by L-3-hydroxyacyl CoA dehydrogenase (EC 1.1.1.35) (Berg et al., 2012; Lehninger et al., 2008).

In the last step (thiolysis), the previously formed 3-ketoacyl CoA is cleaved by the thiol group of a free coenzyme A molecule, yielding acetyl CoA and an acyl CoA molecule shortened by two carbon atoms. This reaction is catalyzed by acyl CoA acetyltransferase (thiolase, EC 2.3.1.16) (Berg et al., 2012; Lehninger et al., 2008).



Adapted from Berg et al. (2012)

Illustration 10. β -oxidation involves 4 main steps: oxidation, hydration, oxidation and thiolysis.




Adapted from Lehninger et al. (2008)

Illustration 11. After β-oxidation, the main resultant product, acetyl CoA, enters the Citric Acid Cycle for e⁻ production that can be transported via NADH and FADH₂ carriers to enter the respiratory chain for ATP synthesis.

3.2.4. Degradation of Unsaturated Fatty Acids

Oxidation of UFAs requires up to two additional reactions compared to the previously described oxidation sequence. The double bonds present in these FAs are frequently in *cis* configuration, which prevents them from being hydrated on the second degradation reaction. This is because enoyl CoA hydratase, the enzyme responsible for catalyzing the addition of H₂O, operates only on *trans* double bonds. Besides, the presence of a double bond between C-3 and C-4 prevents the formation of another double bond between C-2 and C-3. The solution to this problem comes from *cis*-Δ³-enoyl CoA isomerase (EC 5.3.3.8), an enzyme capable of shifting the position and configuration of the *cis*-Δ³ double bond to a *trans*-Δ² double bond. The substrate is now similar to those of the SFA oxidation sequence and β-oxidation can proceed (Berg et al., 2012; Lehninger et al., 2008) (illustration 12).




Adapted from Lehninger et al. (2008)

Illustration 12. The full oxidation of a monounsaturated fatty acid (MUFA) involves the action of an isomerase to change the double bond location and configuration.

Polyunsaturated fatty acids (PUFAs), have more than one double bond and require an additional reaction to get fully oxidized.

At some point of the β -oxidation pathway, a stalemate occurs from the formation of a *trans*- Δ^2 , *cis*- Δ^4 -dienoyl CoA intermediate which is not a substrate for *trans*-enoyl CoA hydratase and therefore, cannot be directly hydrated. Nevertheless, 2,4-dienoyl CoA reductase (EC 1.3.1.34), a NADPH-dependent enzyme can convert this substrate to *trans*- Δ^3 -enoyl CoA. This new substrate can now be converted by *cis*- Δ^3 -enoyl CoA isomerase to *trans*- Δ^2 -enoyl CoA and full oxidation can proceed normally (Berg et al., 2012) (illustration 13).




Adapted from Lehninger et al. (2008)

Illustration 13. The full oxidation of a polyunsaturated fatty acid involves the action of an isomerase and a reductase.

3.3. Dietary Lipid Absorption

Most of ingested lipids come in the form of triacylglycerols and must be degraded so they can be absorbed in the intestinal epithelium (illustration 14). Dietary triacylglycerols are emulsified in the small intestine lumen by bile salts, stored in the gallbladder, and hydrolyzed into FFAs and monoacylglycerol by water-soluble intestinal lipases, secreted by the pancreas. These products cross the intestinal mucosa, where they are reconverted to triacylglycerols and are incorporated, along with cholesterol and apolipoproteins, into lipoprotein transport particles known as chylomicrons (Berg et al., 2012; Lehninger et al., 2008).

Chylomicrons are released into the lymphatic system and then into the blood, which transports them to muscle and adipose tissue. On the capillaries, apolipoprotein C-II present in chylomicrons activates lipoprotein lipase, which hydrolyses triacylglycerols to FAs and glycerol. The FAs can then be taken by the target tissue cells, where they can be oxidized for energy (myocyte) or reesterified for storage as triacylglycerols (adipocyte) (Berg et al., 2012; Lehninger et al., 2008).



Adapted from Lehninger et al. (2008)

Illustration 14. Absorption of dietary lipids in vertebrates.

3.4. *De Novo* Synthesis


The excess dietary carbohydrates and proteins can be converted/recycled to FAs and then incorporated into triacylglycerols for storage in a process known as *de novo* synthesis. Generally, this endogenous lipogenic pathway for FA biosynthesis becomes unnecessary when the body's lipid requirements are attained in the diet. Nevertheless, this synthesis is particularly important during embryonic development and lactation in mammary glands (Berg et al., 2012; Strable and Ntambi, 2010).

The final product of this synthesis is palmitate, a sixteen carbon SFA that is the precursor for the formation of other FAs in a task involving other enzymatic systems. *De novo* synthesis occurs in the cytoplasm of hepatic, renal and adipose tissue cells besides lactating mammary glands. This process can be divided into two distinct stages: activation of acetyl CoA and the set of reactions of the fatty acid complex (Berg et al., 2012).

3.4.1. Activation – acetyl CoA carboxylation

The end-product of FA degradation, acetyl-CoA, is now the precursor and source of carbons for the synthesis of any FA while the reductant role is played by NADPH molecules. Therefore, the first step of *de novo* synthesis is to obtain acetyl CoA and its further activation (Berg et al., 2012).

Acetyl CoA is a common organic intermediate product of oxidation of pyruvate, FAs, amino acids and ketone bodies. Nevertheless, the mitochondrial membrane is impermeable to acetyl CoA. Acetyl CoA must be conjugated with oxaloacetate to form citrate, in a reaction catalyzed by citrate synthase (EC 2.3.3.1). Citrate can then be freely transferred to the cytoplasm through the citrate carrier (CiC). These mitochondrial transporters play an important intermediary metabolic role, connecting carbohydrate catabolism and lipogenesis, by facilitating an exchange flow of citrate and malate between the mitochondrial matrix and the cytosol, respectively (illustration 15). In fact, CiC helps citrate get through the permeable inner mitochondrial membrane, which is then transported by passive diffusion from the mitochondrial outer membrane to the cytosol through voltage dependent anion channels. In the cytoplasm, citrate is then cleaved to acetyl CoA and oxaloacetate, in a reaction catalyzed by ATP citrate lyase (EC 2.3.3.8.) In addition, cytosolic citrate can provide, via malic enzyme or NADP malate dehydrogenase (EC 1.1.1.40), reducing equivalents as NADPH molecules that are required in further lipogenesis phases. Nevertheless, most of required NADPH for FA synthesis comes from the pentose phosphate pathway (Gnoni et al., 2009).




Adapted from Gnoni et al. (2009)

Illustration 15. The metabolic key role played by the CiC providing a linkage between glycolysis and lipogenesis. HMGCoA, 3-hydroxy-3-methylglutaryl-CoA; PyC, pyruvate carrier.


(a) Pyruvate dehydrogenase, (b) citrate synthase, (c) ATP-citrate lyase, (d) acetyl-CoA carboxylase, (e) fatty acid synthase, (f) 3-hydroxy-3-methylglutaryl-CoA reductase, (g) cytosolic malate dehydrogenase, (h) mitochondrial malate dehydrogenase, (i) malic enzyme.

Carboxylation of acetyl CoA expresses the beginning of *de novo* synthesis, a reaction catalyzed by acetyl CoA carboxylase (ACC). This process is irreversible and results in the formation of the substrate malonyl CoA (illustration 16). ACC in animals is a single multifunctional polypeptide that has three functional domains (see illustration 17): the biotin carboxylase, which activates a carboxyl group derived from hydrogencarbonate in an ATP-dependent reaction; the biotin carrier protein, which accepts the activated carboxyl group binding it to a nitrogen in the biotin ring; and the transcarboxylase, which is responsible for the transfer of the activated carboxyl group from the carboxybiotin intermediate to acetyl CoA yielding malonyl CoA (Berg et al., 2012; Lehninger et al., 2008).



Adapted from Berg et al. (2012)


Illustration 16. The first step of *de novo* synthesis comprises the carboxylation of acetyl CoA into malonyl CoA.



Adapted from Lehninger et al. (2008)

Illustration 17. The acetyl CoA carboxylase is a three subunit polypeptide that mediates the carboxylation of acetyl CoA to malonyl CoA.


This reaction is the rate-limiting step in FA synthesis, with ACC playing a key role in controlling the balance between oxidation and synthesis in the metabolism of FAs. Inactivation of ACC occurs by phosphorylation in an ATP-dependent reaction catalyzed by AMPK that dissociates the polypeptide into monomeric subunits which causes loss of activity (see illustration 18). AMPK works as a fuel gauge since it's activated by AMP and inhibited by ATP. Therefore, in circumstances of low cellular energy levels, cells tend to stop synthesizing new lipids. On the other hand, protein phosphatase 2A (EC 3.1.3.16) catalyzes the inverse reaction, the activation of ACC by dephosphorylation (Berg et al., 2012; Lehninger et al., 2008).



Adapted from Berg et al. (2012)

Illustration 18. Regulation of acetyl CoA carboxylase by phosphorylation/dephosphorylation.

The flow of precursors into malonyl CoA can also be regulated by hormones and substrates (illustration 19). Citrate stimulates allosterically ACC activity. High levels of citrate induce polymerization of inactive subunits that can partly reverse the inhibition produced by phosphorylation. On the other hand palmitoyl CoA, the main product of FA synthesis, inhibit ACC activity by causing the same effects as phosphorylation, dissociating the ACC polypeptide into inactive subunits. Palmitoyl CoA also limits FA synthesis by inhibiting CiC, preventing the entry of citrate from the mitochondria into the cytosol. Glucagon and epinephrine, under conditions of fasting and exercise, stimulate the mobilization of FAs from triacylglycerols in cell depots which will be used as urgent energy source. These hormones also inhibit FA synthesis by inhibiting acetyl CoA carboxylase and though the exact mechanisms are not yet entirely understood, it is recognized that they enhance the inhibition provoked by the activity of AMPK by phosphorylating ACC (Berg et al., 2012; Lehninger et al., 2008).



Adapted from Lehninger et al. (2008)

Illustration 19. Control on the FA biosynthesis by hormonal triggers and other substrate factors.

FA synthesis and oxidation are opposite operations that, if performed simultaneously, would result in a nonsense wasting energy strategy. Therefore, these two major lipid metabolic processes have to be permanently and tightly regulated. For example, the first intermediate product of the activation of acetyl CoA in *de novo* synthesis, malonyl CoA, is responsible for inhibiting the key transporter in β -oxidation, carnitine acyltransferase I, preventing the formation of the intermediate acyl carnitine (Berg et al., 2012; Lehninger et al., 2008).


3.4.2. Reactions of the Multi Enzymatic Fatty Acid Synthase (FAS) Complex


Long carbon chain FAs are assembled in multiple repeated four-step cycles comprehending: condensation, reduction, dehydration, and reduction (see illustration 20). Each cycle yields two carbon atoms to the acyl chain, which is the substrate for the next cycle with an activated malonyl CoA group. For the complete synthesis of palmitate (C16:0) the cycle must be repeated seven consecutive times (Berg et al., 2012; Lehninger et al., 2008).

These reactions are operated by a multifunctional enzyme complex, fatty acid synthase (FAS, EC 2.3.1.85). This enzyme is a dimer of identical 270 kDa subunits. Each subunit presents a set of seven successive enzymes and a protein, acyl carrier protein (ACP), that together make up a fully functional enzymatic system capable of synthesizing a 16 carbon SFA (Berg et al., 2012; Lehninger et al., 2008).

ACP is responsible for coordinating and carrying the reaction intermediates throughout the several enzymes active sites in each cycle. The bond of ACP to the intermediates is similar to the one that occurs in FA degradation between CoA and the intermediates. On both cases, the intermediates are linked to the sulfhydryl terminus of a phosphopantetheine group. In ACP this group is attached to a serine residue (Berg et al., 2012; Lehninger et al., 2008).

Elongation stage starts with the linkage of acetyl CoA and malonyl CoA to ACP. This reaction, catalyzed respectively by acetyl transacylase and malonyl transacylase (or malonyl-acetyl transferase), results in the formation of acetyl ACP and malonyl ACP. In both reactions coenzyme A is released (Berg et al., 2012; Lehninger et al., 2008), as we can see in the following reactions:






Adapted from Berg et al. (2012)

Illustration 20. The basic steps of one cycle in FA synthesis.

The condensation reaction is catalyzed by β -ketoacyl synthase and comprises the formation of acetoacetyl ACP from the reaction of acetyl ACP with malonyl ACP where CO_2 is also released (Berg et al., 2012; Lehninger et al., 2008):



This reaction is known as condensation reaction because it results in the formation of a four carbon compound from a two and three carbon units, acetyl ACP and malonyl ACP, respectively (Berg et al., 2012).


In the next step, acetoacetyl ACP undergoes reduction of the carbonyl group at C-3 to form D-3-hydroxybutyryl ACP, a reaction catalyzed by β -ketoacyl reductase where NADPH acts as an electron donor. This reaction opposes the one occurring in FA degradation and exemplifies the principle that NADPH is consumed in biosynthetic reactions and NADH is generated in energy-yielding reactions (Berg et al., 2012).

The third step requires the deletion of water elements present in C-2 and C-3 of D-3-hydroxybutyryl ACP to yield a double bond, resulting in the formation of trans- Δ^2 -enoyl ACP or crotonyl ACP. This dehydration reaction is catalyzed by 3-hydroxyacyl-ACP dehydratase (Berg et al., 2012; Lehninger et al., 2008).

The completion of one cycle is concluded with a second reduction reaction in the double bond location of crotonyl ACP, which is reduced to butyryl ACP. This reaction is catalyzed by enoyl ACP reductase and again uses NADPH as reductant (Berg et al., 2012; Lehninger et al., 2008).


The resultant four carbon compound of the first round of FA synthesis, butyryl ACP, is the main substrate for the second cycle that starts by condensing it with malonyl ACP to form C_6 - β -ketoacyl ACP, a reaction much similar to the one in the first cycle. The elongation cycles continue until C_{16} acyl ACP is produced and, at that moment, a thioesterase hydrolyzes this intermediate producing palmitate and ACP. One molecule of H_2O is consumed to break this bond (Berg et al., 2012; Lehninger et al., 2008).

The overall reaction for the synthesis of palmitate, from acetyl CoA already present in the cytosol, can be expressed by the following equation (Berg et al., 2012):



3.5. Biosynthesis of Long-Chain SFAs, MUFAs and PUFAs

Further elongation and unsaturation of FAs are achieved by accessory enzymatic systems on the precursor palmitate (illustration 21). Longer FAs such as stearate (C18:0) and others are produced in reactions catalyzed by enzymes located in the cytoplasmic face of the endoplasmic reticulum membrane. These enzymes, known as elongases, are responsible for adding two-carbon units to the carboxyl ends of the acyl substrates. In these reactions, CoA rather than ACP is the acyl carrier, but the sequence of events is similar to that in palmitate synthesis. Condensation occurs again by decarboxylation of malonyl CoA that remains the two-carbon donor which precedes reduction, dehydration and reduction (Berg et al., 2012; Hussain et al., 2013; Lehninger et al., 2008).



Adapted from Lehninger et al. (2008)


Illustration 21. Biosynthesis of MUFAs and PUFAs derive from palmitate synthesis with accessory enzyme systems. FAs shaded pink cannot be produced by mammals and have to be ingested in the diet.

Working cooperatively with elongases in the production of various MUFAs and PUFAs are another group of enzymes known as desaturases (EC 1.14.19). These enzymes catalyze the introduction of a C-C double bond in different locations of the aliphatic chain of an acyl CoA substrate (Berg et al., 2012; Hussain et al., 2013; Lehninger et al., 2008).

In humans, for example, four families of desaturases are fully documented: Δ^9 desaturase (EC 1.14.19.1), mainly responsible for the production of two of the most common MUFAs, palmitoleic and oleate, establishing a double bond between C-9 and C-10; and Δ^4 , Δ^5 , Δ^6 desaturases which are responsible for introducing double bonds in the carbon positions 4, 5 and 6, respectively (Hussain et al., 2013).

MUFAs are formed in mammalian systems by direct oxidative desaturation in which the removal of two hydrogen results in the formation of a double bond (Berg et al., 2012; Lehninger et al., 2008; Vance and Vance, 2008).

Conversion of stearoyl CoA into oleoyl CoA, for example, is a complex process mediated by three proteins located in the endoplasmic reticulum membrane (NADH-cytochrome b_5 reductase, cytochrome b_5 and a desaturase) that requires an electron donor such as NADH or NADPH and molecular oxygen (Berg et al., 2012; Lehninger et al., 2008; Vance and Vance, 2008):



The reaction involves an electron transport system that starts by the transfer of electrons from NADPH to the FAD present on the enzyme NADH-cytochrome b_5 reductase, reducing it to FADH_2 (illustration 22). The heme iron (III) atom of cytochrome b_5 can then be reduced to iron (II) which provokes a conversion of the nonheme iron (III) atom of the desaturase, in this case Δ^9 desaturase or stearoyl CoA desaturase (SCD), into iron (II). SCD can now react with O_2 and the saturated acyl CoA substrate that in this case is stearoyl CoA. Besides the formation of a double bond in C-9 present in oleoyl CoA, this reaction also releases two H_2O molecules. In this desaturation process, the rate-limiting factor is SCD (Berg et al., 2012; Lehninger et al., 2008; Ren et al., 2004; Vance and Vance, 2008).




Illustration 22. The desaturation of a FA involves an electron-transport chain.

MUFAs synthesized by SCD, namely palmitoleate (16:1, Δ^9) and oleate (18:1, Δ^9), are then used as substrates for the synthesis of various lipid classes including phospholipids, triacylglycerols and cholesteryl esters (Vance and Vance, 2008).

Mammalian hepatocytes cannot establish double bonds beyond the C-9 position of fatty acids. Therefore mammals cannot convert linoleate (18:2, $\Delta^{9,12}$), or α -linolenate (18:3, $\Delta^{9,12,15}$) which are required in the diet as essential FAs because they are necessary precursors for the synthesis of other products (Hussain et al., 2013; Lehninger et al., 2008).

4. Fatty Acid Synthase

4.1. Structure and Activity of the Mammalian FAS Complex


Fatty acid synthase multienzyme complex is a dimer composed of identical 270-kD multifunctional polypeptides that occurs in living organisms in two distinct types, FAS I and FAS II. The first can be found in vertebrates and fungi while the latter is present on plants and bacteria (Lehninger et al., 2008).

While in type II systems every catalytic function is provided by individual enzymes, in type I all necessary catalytic centers are aggregated in a single polypeptide chain. In the mammalian FAS I, for example, seven active sites for different reactions lie in separate domains, with each catalytic site participating in the last step of *de novo* synthesis (illustration 23). Therefore, within each monomeric subunit, seven active domains can be found: malonyl-acetyl transferase (MAT); ketoacyl synthase (KS); ketoacyl reductase (KR); dehydratase (DH); enoyl reductase (ER) and thioesterase (TE), besides ACP for transport of acyl conjugates throughout each catalytic center (Berg et al., 2012; Maier et al., 2008) (illustration 24).

The overall swine FAS structure described by Maier et al. (2008) identifies two additional nonenzymatic domains: a pseudo-ketoreductase and a peripheral pseudo-methyltransferase. These residual structures are thought to be of an ancestral methyltransferase domain that can still be found in polyketide synthases, a class of multienzymatic complexes that produce secondary metabolites known as polyketides such as erythromycin. Nevertheless, the ACP and TE domains are still undetermined in pigs.

Each monomer adopts a coiled conformation allowing multiple intra- and inter-monomer functional domain interactions with the KS domains located in the central core of the structure. In mammals, MAT is a bifunctional protein domain that catalyzes the

transfer of malonyl and acetyl groups from malonyl CoA and acetyl CoA to ACP, respectively (Maier et al., 2008).



Adapted from Maier et al. (2006)

Illustration 23. Final cyclic reaction in palmitate synthesis mediated by FAS complex.



Adapted from Maier et al. (2008)




Illustration 24. Front view and linear organization schemes of the mammalian FAS with respective catalytic sites colored. Linker domains (LD) are highlighted in gray. DH1 and DH2 represent two dehydratase modules, however, only one is active.

As shown in chapter 3, FAS plays a central role in energy homeostasis by converting excess dietary consumption into storage lipids that can later provide energy via β -oxidation.

FAS activity can be found almost in every tissue, though higher enzymatic expression levels can only be found within lipogenic tissues, namely in adipocytes, hepatocytes and lactating mammary glands (Jayakumar et al., 1995).

In humans, its expression is upregulated by diet carbohydrates, particularly by simple sugars. This occurrence is particularly noticeable after a fasting period. This regulation occurs mostly at a pretranslational phase by controlling mRNA levels. This stimulation is highly associated with insulin since FASN mRNA levels do not increase in diabetic rats and, on the contrary, an increase on FASN expression can be found in hyperinsulinemic rat livers. On the other hand, glucagon suppresses FASN transcription through cAMP-dependent mechanisms (Hopperton, 2012; Semenkovich, 1997).

Fatty acid synthesis in the liver and adipose tissues is strongly decreased by small amounts of exogenously supplied fatty acids. Furthermore, dietary/exogenous PUFAs decrease FAS expression, particularly alpha-linolenic (C18:3, $\Delta^{9, 12, 15}$), docosahexaenoic (C22:6, $\Delta^{4, 7, 10, 13, 16, 19}$), eicosapentaenoic (C20:5, $\Delta^{5, 8, 11, 14, 17}$) and arachidonic (C20:4, $\Delta^{5, 8, 11, 14}$), which have been shown to suppress FAS expression in the liver and adipose tissue (Hopperton, 2012; Semenkovich, 1997).

In non-lipogenic tissues, FASN expression is modulated through hormonal signaling. Besides insulin and glucagon, thyroid hormone and glucocorticoids increase FASN expression. Furthermore, estrogen and progesterone are also associated with elevated FASN expression. Transcription factors such as sterol regulatory element binding protein 1-c (SREBP1-c) mediate the regulation of FAS transcription by hormonal signals (Hopperton, 2012; Semenkovich, 1997).

Various compounds have been discovered and designed to inhibit FASN expression with the particular interest as anti-obesity drugs and for antitumoral treatments. Cerulenin and its derivatives, particularly C75 and C93, are small designed molecules that have showed inhibitory effects on FASN, by targeting the ketoacyl synthase domain, besides significant antitumoral effects. Orlistat is an FDA approved anti-obesity drug that inhibits FASN expression, by binding and inhibiting the thioesterase domain activity. Other inhibitors of FASN activity include epigallocatechin-3-gallate (EGCG) and other natural flavonoids (Hopperton, 2012; Liu, 2008; Loftus et al., 2000).

Clop et al. (2003) proposed FASN as candidate gene for FA composition. Ever since, more and more studies have pointed out the potential influence of this gene SNPs on porcine FA composition and meat quality (Corominas et al., 2013; Kim et al., 2011; Maharani et al., 2012; Munoz et al., 2007; Munoz et al., 2003).

Other authors as Berndt et al. (2007) propose FASN to be as well a candidate gene for the study of metabolic disorders as obesity and type 2 diabetes because of its central role in FA lipogenesis. They have shown that increased FASN expression in adipose tissue is associated to excess energy intake and accumulation of body fat. Furthermore, they state that adipose FASN mRNA expression might significantly mislead insulin sensitivity and circulating adipokine patterns.

4.2. FAS gene sequence and polymorphisms

Eukaryotic genes are organized in exons and introns. Exons are the sequences that encode for the protein, while introns are non-expressed sequences that get removed during maturation of pre-mRNA.

Genetic polymorphisms on coding sequences (exons) are occurrences that induce genetic variation, adaptation and biodiversity. SNPs are the most common genetic variations in which a single nucleotide is substituted, deleted or added in the transcribed sequence. These polymorphisms may affect the overall expression of the triplet (non-synonymous SNPs) or not (synonymous SNPs) (Kimball, 1994).

FASN is a highly conserved gene among mammals. Swine (*Sus scrofa*) FASN (accession number NM_001099930.1) shares 85% of identity with that of the cow (*Bos taurus*) (accession number: NM_001012669.1) and of the goat (*Capra hircus*) (accession number DQ223929.1), 83% with humans (*Homo sapiens*) (accession number NM_004104.4) and 79% with mouse (*Mus musculus*) (accession number AF127033.1) with 93% sequence coverage.

The main objective of this work was to obtain the coding FASN sequence in AL pigs in subcutaneous adipose tissue and to compare it with that of the domestic pig (*Sus scrofa*). To our knowledge, there is no information regarding the genomic organization of genes of lipogenic enzymes in the obese AL pig, including fatty acid synthase. Bibliographic references are also scarce.

III. MATERIAL AND METHODS

1. Slaughter conditions and tissue collection

The purebred Alentejano pig from where biological samples were collected was fed a commercial diet (Proibérico 2, Provimi, Alverca, Portugal). The specific composition of this diet is proprietary information. The commercial diet provided 150 g/kg crude protein, 30 g/kg crude fat (with ~60% of oleic and linoleic acids), and 13.0 MJ digestible energy.

Samples were collected from one purebred AL pig (P) in an industrial slaughterhouse. This animal was killed at 100 kg BW by electronarcosis and bleeding. Tissue samples were obtained from subcutaneous adipose tissue, snap frozen in liquid nitrogen and stored at -80 °C until analysis.

2. RNA extraction

Total RNA extraction from the collected subcutaneous adipose tissue (SUB) was performed using the commercial GeneJET™ RNA Purification Kit (Thermo Scientific). Up to 100 mg of tissue were disrupted using a conventional rotor-stator homogenizer, Precellys® Minilys (Bertin Technologies), in a 10 s at 5000 rpm two cycle program with a 10 s rest time between cycles, following the manufacturer's instructions. Assessment of total RNA integrity was performed using a NanoDrop® 2000 Uv-Vis Spectrophotometer (Thermo Scientific) at 260 nm and purified RNA was stored at -80 °C until use.

3. Complementary DNA synthesis

The first strand cDNA synthesis reaction, namely Reverse Transcription (RT) reaction, was performed according to Maxima® First Strand cDNA Synthesis Kit for RT-qPCR reactions (Thermo Scientific). This commercial kit produces cDNA with both oligo (dT)₁₈ and random hexamer primers. The resulting cDNA product was stored at -20 °C until usage.


4. cDNA Amplification by PCR

Amplification by polymerase chain reaction (PCR) enables a fast and convenient acquirement of multiple specific DNA pieces, set by a pair of oligonucleotide primers that flank the target sequence region.

Briefly, PCR reactions stand for multiple repeated cycles of heating, cooling and heating, allowing denature of double stranded DNA, binding of primers and synthesis of complementary DNA by a *Taq* polymerase, respectively, that generate countless double stranded target DNA sequence molecules (illustration 25).

In RT-PCR in particular, the first PCR cycle starts with denaturation of the molecule produced in reverse transcription, a double stranded molecule of RNA and complementary DNA, therefore, only one DNA template is yielded.

All PCR reaction were programmed and performed in a MyCycler™ Thermal Cycler (Bio-Rad).



Adapted from Brown (2010)

Repeat the cycle 35 times

Illustration 25. The basic steps in polymerase chain reaction; DNA denaturation, primer annealing and extension.

4.1. Sequencing Strategy

The *Sus scrofa* FASN complete coding sequence (cds) was retrieved from NCBI database, with the reference number NM_001099930.1 as guidance for the AL pig sequencing strategy. Then, specific target regions were conceived for consecutive partial sequencing of the gene based on sets of primers available on literature and newly designed ones (illustration 26). For amplification and cloning of the 5' and 3' ends, rapid amplification of cDNA end's (RACE) technique was performed.




Illustration 26. Partial sequencing strategy for the fatty acid synthase gene.

4.2. Primer Design

Little was found in current literature about *Sus scrofa* FASN sequencing strategies and specific primer sequences, nevertheless, five pairs of previously described primer sequences were fully tested, namely FAS S/AS (Huang et al., 2007), FASN1-FW/FASN1-RV and FASN2-FW/FASN2-RV (Munoz et al., 2003), FASN39-FW/FASN39-RV and FASN40-FW/FASN40-RV (Kim et al., 2011). Still, only the latter two pairs gave products successfully amplified and sequenced.

Since there weren't much swine FASN primer sequences available in current literature, several sets of primer pairs were designed using specific Biosoftware tools such as Primer3Web version 4.0.0, NetPrimer (PREMIER Biosoft) and BioEdit Sequence Alignment Editor Version 7.1.7. All primers that successfully amplified FASN gene sequences are listed and described on table 2. For a complete list of tested primers check appendix I (Hall, 1999; Untergasser et al., 2012).

Table 2. Complete list of primers used in FASN sequencing along with respective sequence, gene location regarding to swine FASN record NM_001099930.1 on GenBank, annealing temperature and amplified product size.

Primer Designation	Gene Location (bp)	5' → 3' Sequence	Annealing Temperature (°C)	Amplified Product size (bp)
FAS D FW	4881-4902	CCACCTCTGTTCTGCTGCTTCA	65	685
FAS D RV	5546-5565	CAGGGCAAGCACATAGGCAA		
FAS L FW	5393-5415	ATCCTGCTGGACTCGCTCTTTGA	65	783
FAS L RV	6158-6175	CGGCACGACGGGCTCCCA		
FAS Q FW	6108-6130	CCAACTACGGCTTCGCCAACTCT	65	660
FAS Q RV	6746-6767	CGATGGGGTGGACCAGGAACAG		
FASN exon39-FW	6615-6631	CGGCGACTCCCACATCC	60	431
FASN exon39-RV	7025-7045	GAAGGTGTGTGAGCCGTCGAA		
FASN exon40-FW	6908-6928	CCCGAGGGGCCTTACCGCATC	60	378
FASN exon40-RV	7268-7285	GAAGGAGCGAGCGGCGAA		
FAS F FW	7015-7035	CCTCTTCCTGTTTCGACGGCTC	58	497
FAS F RV	7490-7511	TGTGGATGATGCTGAGGATGGA		

4.3. PCR Protocol Optimization

PCR reactions were performed with multiple conditions and reagents in PCR specific tubes.

DNA fragment “D” amplification was assembled with: 0.3 mM of a deoxynucleotide triphosphates (dNTPs) mixture, 0.2 μ M of each primer, 50 ng of DNA template, 1x DreamTaq buffer (containing optimized concentrations of KCl and $(\text{NH}_4)_2\text{SO}_4$ and 2 mM MgCl_2) and 2.5 U of DreamTaq DNA Polymerase (Thermo Scientific) in a total reaction volume of 50 μ L. The amplification program executed was: 94 °C for 3 min; followed by 35 cycles of 94 °C for 45 s, 65 °C for 50 s and 60 s at 72 °C; a final extension step at 72 °C for 10 min was also performed.

DNA fragment “L” amplification was assembled with: 0.3 mM of a dNTPs mixture, 0.2 μ M of each primer, 50 ng of DNA template, 1x DreamTaq buffer (containing optimized concentrations of KCl and $(\text{NH}_4)_2\text{SO}_4$ and 2 mM MgCl_2) and 2.5 U of DreamTaq DNA Polymerase (Thermo Scientific) in a total reaction volume of 50 μ L. The amplification program executed was: 94 °C for 3 min; followed by 35 cycles of 94 °C for 45 s, 65 °C for 50 s and 60 s at 72 °C; a final extension step at 72 °C for 10 min was also performed.

DNA fragment “Q” amplification was assembled with: 0.3 mM of a dNTPs mixture, 0.2 μ M of each primer, 50 ng of DNA template, 1x DreamTaq buffer (containing optimized concentrations of KCl and $(\text{NH}_4)_2\text{SO}_4$ and 2 mM MgCl_2) and 2.5 U of DreamTaq DNA Polymerase (Thermo Scientific) in a total reaction volume of 50 μ L. The amplification program executed was: 94 °C for 3 min; followed by 35 cycles of 94 °C for 45 s, 65 °C for 50 s and 60 s at 72 °C; a final extension step at 72 °C for 10 min was also performed.

DNA fragment “exon39” amplification was assembled with: 0.2 mM of a dNTPs mixture, 0.3 μ M of each primer, 46 ng of DNA template, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl_2 and 2.5 U of *Taq* DNA Polymerase (Invitrogen) in a total reaction volume of 50 μ L. The amplification program used was: 94 °C for 5 min; followed by 35 cycles of 94 °C for 45 s, 60 °C for 45 s and 60 s at 72 °C; at the end the reaction was submitted to a final extension step at 72 °C for 5 min.

DNA fragment “exon40” amplification was assembled with: 0.2 mM of a dNTPs mixture, 0.3 μ M of each primer, 46 ng of DNA template, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl_2 and 2.5 U of *Taq* DNA Polymerase (Invitrogen) in a total reaction volume of 50 μ L. The amplification program used was: 94 °C for 5 min; followed by 35 cycles of 94 °C for 45 s, 60 °C for 45 s and 60 s at 72 °C; at the end the reaction was submitted to a final extension step at 72 °C for 5 min.

DNA fragment “F” amplification was assembled with: 0.3 mM of a deoxynucleotide triphosphates (dNTPs) mixture, 0.2 μ M of each primer, 59 ng of DNA

template, 1x DreamTaq buffer (containing optimized concentrations of KCl and $(\text{NH}_4)_2\text{SO}_4$ and 2 mM MgCl_2) and 2.5 U of DreamTaq DNA Polymerase (Thermo Scientific) in a total reaction volume of 50 μL . The amplification program executed was: 94 °C for 2 min; followed by 35 cycles of 94 °C for 30 s, 58 °C for 50 s and 60 s at 72 °C; a final extension step at 72 °C for 10 min was also performed.

Further PCR products (for amplification of different gene fragments) were tested with different conditions and reagents, particularly: annealing temperature ranging 50-70 °C; extension time ranging 60-360 s; different MgCl_2 concentrations; different primer and dNTPs concentrations and *Taq* polymerases (mainly DreamTaq DNA Polymerase (Thermo Scientific), *Taq* DNA Polymerase (Invitrogen), *Taq* DNA Polymerase (Thermo Scientific), Supreme NZYTaq DNA polymerase (NZYTech), NZYTaq DNA polymerase (NZYTech) and NZYTaq 2x Green Master Mix (NZYTech)).

Adding bovine serum albumin (BSA) and dimethyl sulfoxide (DMSO) in the PCR reaction mixtures was also tested. Moreover, primers of different sets were paired and tested to attempt amplification of longer products.

5. Electrophoresis and Purification of PCR products

In order to separate PCR products a 1% (w/v) agarose gel electrophoresis was performed. This universal technique can isolate different length DNA fragments, enabling a qualitative and quantitative overview of the amplified product when compared with a DNA ladder marker.

Tris-Borate-EDTA (TBE) 0.5X buffer (50 mM Tris, 45 mM boric acid, 0.5 mM EDTA, pH 8.5) was used as electrophoresis buffer. PCR samples were loaded with 1X Orange DNA Loading Dye (100 ml: 400 mg Orange G, 40 mg sucrose) and 1X GelRed™ Nucleic Acid Gel Stain (Biotium). NZYDNA Ladder Marker III (NZYTech) was used as molecular marker. Gels ran for 1 - 2 h at 80 V and were visualized and photographed under UV light using a Kodak DC 120 camera (Sambrook et al., 1989).


Expected product size bands were sliced out of the gel, when the product contained unspecific.

DNA purification and concentration was performed using illustra™ GFX™ PCR DNA and Gel Band Purification Kit (GE Healthcare) for both direct purification from a PCR mixture or TBE agarose gel slice. The protocol is straightforward and includes the basic principles of sample capture, sample binding, wash and dry terminating with an elution step. Purified DNA was stored at -20 °C until used.

An additional electrophoresis was performed after purification in order to confirm purified DNA integrity.

6. Cloning of PCR products

Modern genetic engineering techniques, particularly gene cloning, offer a rapid and efficient way to sequence target genes based on recombinant DNA technology. Gene cloning consists on the process of making copies or clones of a single target gene by assembling DNA recombinant molecules and replicating them in a host organism (see illustration 27).



Adapted from Brown (2010)

Illustration 27. The basic steps of gene cloning.

First, recombinant strands of DNA are to be made where plasmids are often used as vectors to transport the genes of interest to host cells.

Transformation is the process that comprises the transmission of the plasmid into a new host cell. This step requires that the host cells become “competent” in order to temporarily allow the entrance of extra DNA material; this can easily be achieved by a sudden change in environmental conditions such as temperature.


Escherichia coli (*E. coli*) are commonly used as hosts for DNA cloning and sequencing. Upon transformation of *E. coli* with a recombined vector carrying a gene of interest, the bacteria multiply the gene of interest while maintaining the integrity of its content.

Detection of transgenic cells is generally accomplished by expression of antibiotic resistance genes carried by the plasmids. Another common way of selection depends on the presence of proteins such as the X-Gal/ *lacZ* system.

6.1. Cloning vectors

6.1.1. pGem®-T Easy Vector cloning system

The pGem®-T Easy Vector (Promega) is a high copy cloning vector with *ca.* 3.0 Kb of double stranded linearized DNA. This vector includes a gene for antibiotic resistance to ampicillin (*Amp^r*) and a gene for the enzyme β -galactosidase (*lacZ*) that contains the cloning site (illustration 28).



Adapted from pGem®-T and pGem®-T Easy Vector Systems

Illustration 28. pGem®-T Easy Vector Map and points of interest, namely, *Amp^r* and *lacZ* gene locations.


Cloning with this vector involves selection of transformants on ampicillin agar as well as screening for β -galactosidase activity to identify recombinants.

β -galactosidase is an enzyme that hydrolyzes a β -glycosidic bond as in lactose degradation producing galactose and glucose. In the presence of X-Gal (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside), a lactose analog, the enzyme cleaves this specific bond inducing the production of galactose and 5-bromo-4-chloro-3-hydroxyindole. This compound is subsequently transformed into 5,5'-dibromo-4,4'-dichloro-indigo, via dimerization and oxidation, an insoluble blue product.

The expression of *lacZ* gene is induced by the lactose analog promoter IPTG (isopropyl- β -D-thiogalactopyranoside). The disruption of the *lacZ* gene by insertion of the desired DNA leads to white colonies defining lack of enzyme activity. On the other hand, blue colonies stand for non-recombinant bacteria that synthesized β -galactosidase and degraded X-Gal.

6.1.2. NZY-A PCR cloning kit

The pNZY28-A (NZYTech) is a high copy cloning vector with *ca.* 2.88 kb of double stranded linearized DNA that includes a gene for antibiotic resistance to ampicillin (Amp) and a *lacZ* gene. The cloning site is located in the *lacZ* gene for easy detection of recombinants by screening for β -galactosidase activity as with pGEM®-T Easy Vector (Promega) (illustration 29).



Adapted from NZY-A Speedy PCR cloning kit

Illustration 29. pNZY28 map and points of interest, namely, Amp and *lacZ* gene locations.

6.2. Plasmid-Insert Ligation

Ligation mixtures were prepared on sterile, nuclease-free microcentrifuge tubes with 5 μ L of buffer, 50 ng of vector, 3 U of T4 DNA ligase and up to a ratio of 3:1 of insert (insert:vector ratio), in a 10 μ L reaction that was incubated for 1 h 30 min at 25 °C.

6.3. Transformation conditions

For *E.coli* transformation, JM109 competent cells (Promega) were used and manufacturer's instructions were followed. 5 μ L of ligation reaction were added for each 50 μ L of competent cells. The resultant mixture rested on ice for 20 min and was, then, subjected to a heat shock at 42 °C for 45 s, before cooling for 2 min on ice. 950 μ L of pre-warmed SOC medium (2% tryptone, 0.5% yeast extract, 0.05% NaCl, 2.5 mM KCl, 10 mM MgCl₂, 20 mM glucose) were added to the mixture and the cells were left growing for 1 h 30 min at 37 °C at 150 rpm on an orbital incubation shaker (Aerotron AG, HT Infors).

Cells were centrifuged at 1000 g for 10 min at room temperature and the resulting pellet was suspended in 70 μ L of the supernatant, plated on low salt LB plates (1% tryptone, 0.5% yeast extract, 0.5% NaCl, pH 7.5, 1.5% agar) supplemented with 100 μ g/mL of ampicillin, 0.5 mM IPTG and 80 μ g/mL X-Gal, for selection of recombinant clones, and incubated overnight at 37 °C.


6.4. Plasmid DNA extraction

Plasmid DNA was extracted from *E. coli* cells using GeneJET Plasmid Miniprep Kit (Thermo Scientific) following manufacturer's instructions, after growing cells in low salt LB medium (1% tryptone, 0.5% yeast extract, 0.5% NaCl, pH 7.5) supplemented with 100 μ g/mL of ampicillin and grown overnight at 37 °C at 150 rpm on an orbital incubation shaker (Aerotron AG, HT Infors). Extracted plasmid DNA was conserved at -20 °C until use.

7. Restriction Assay

In order to confirm the selection of only proper recombinant clones, restriction assays were performed.

Restriction enzymes generally bind onto a specific recognition sequence of a DNA molecule, and subsequently cleave it by making an incision at the phosphate backbone of the double helix structure avoiding damages to the bases (illustration 30).



Adapted from Klug (2012)

Illustration 30. Operation of restriction enzymes – EcoRI.

FastDigest®*EcoRI* (Thermo Scientific) and FastDigest®*NotI* (Thermo Scientific) were the main restriction enzymes used. These endonucleases cut two specific regions of the plasmids, near the cloning site, allowing the linearization of the plasmid, plus the release of the cloned product (see points 6.1.1 and 6.1.2). Manufacturer's instructions were followed and results were viewed by agarose gel electrophoresis as described in point 5.

8. DNA Sequencing and Analysis

DNA sequencing reactions were performed by Macrogen (Netherlands). Sequence analysis was carried out using BioEdit Sequence Alignment Editor Version 7.1.7. and MEGA6. ClustalW Multiple Alignment, NCBI Basic Local Alignment Search Tool (BLAST) program and CAP contig assembly program were the main tools executed (Altschul et al., 1997; Hall, 1999).

9. Rapid Amplification of cDNA Ends

Previously described techniques tend to result in the acquisition of clones that represent only a part of the mRNA's complete sequence. Both missing sequence ends need a proper approach.

First, a RT reaction was performed with the extracted total RNA. Up to 3 µg of total RNA were converted in a final 20 µL reaction with 60 mM oligo d(T) anchor primer (table 3). Initial denaturation was achieved by a 5 min incubation at 70 °C followed by 10 min on ice. Then, reverse transcription was performed in 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl₂, 10 mM DTT, 0.5 mM dNTPs and with 40 U RNase Out (Invitrogen) and 200 U of M-MLV reverse transcriptase (Invitrogen), for 1 h at 37 °C, followed by 10 min at 70 °C for enzyme denaturation.

Table 3. List of primers used for FASN 3' end sequencing.

Primer Designation	Gene Location (bp)	5'→3' Sequence
FAS F RV	7490-7511	TGTGGATGATGCTGAGGATGGA
FAS RACE 3'	7452-7477	CACCGCACGCTGCTGGAGGGC
Oligo d(T) anchor NotI	-	AACCCGGCTCGAGCGGCCGCT ₁₈
Anchor T	-	AACCCGGCTCGAGCGGCCGC

For amplification of the FASN 3' end region a PCR assay was designed with the following conditions: 20 mM Tris-HCl, pH 8.8, 10 mM (NH₄)₂SO₄, 10 mM KCl, 0.1% Triton X-100, 0.1 mg BSA, 2 mM MgSO₄, 0.2 µM of FAS F RV and Anchor T and 2.5 U of *Pfu* DNA Polymerase (Thermo Scientific) in a total reaction volume of 50 µL. The amplification program was: 94 °C for 2 min; 10 cycles of 94 °C for 15 s followed by 55 °C for 30 s and an extension time of 40 s at 72 °C; 94 °C for 15 s; 25 cycles of 94 °C for 15 s followed by 55 °C for 30 s and an extension stage of 72 °C for 40 s with an increment of 20 s each cycle; 72 °C for 7 min. The product was analyzed in a 1% agarose gel that ran for 1 h 30 min at 70 V at constant voltage. Samples were prepared according to what is described in point 5. Expected product size bands were sliced and purified with illustra™ GFX™ PCR DNA and Gel Band Purification Kit (GE Healthcare) according to manufacturer's instructions. Target DNA was cloned with pGEM®-T Easy Vector (Promega) and multiplied in an *E. coli* host as described in point 6. Multiple clones were obtained and sequenced as described in points 6, 7 and 8. However, none of the sequenced clones proved to be a successfully amplified FASN product. Furthermore, another attempt to sequence the FASN 3' end was made using another primer named "FAS RACE 3'" (Table 3), using the same conditions.

IV. RESULTS

1. Fragment amplification detection

PCR amplification produced expected amplicons of the gene that were analyzed by agarose gel electrophoresis gels (illustration 32). Designated specific primers, originated previously calculated amplified products of about 430, 380 and 780 bp, respectively.

PCR products were cloned in pNZY28 (NZYTech) or pGEM®-T Easy Vector (Promega). Multiple clones of each were obtained and sequenced.




Illustration 32. Examples of amplicons generated in PCR assays using distinct primers observed by 1% agarose gel electrophoresis. **A:** Lane M – NZYDNA Ladder Marker III (NZYTech), Lane 1 – PSUBexon39; **B:** Lane M – NZYDNA Ladder Marker III (NZYTech), Lane 1 – PSUBexon40; **C:** Lane M – NZYDNA Ladder Marker III (NZYTech), Lane 1 – PSUBL.

2. Detection of the product after restriction assay

Restriction assays were performed in order to confirm the authenticity of the clones before sequencing. FastDigest®EcoRI (Thermo Scientific) and FastDigest®NotI (Thermo Scientific) were the main restriction enzymes used to digest the plasmid and release the cloned product. Results were observed by electrophoresis of 1% agarose gels (illustration 33).




Illustration 33. Example of an insert release gel after the restriction assay. A: Lane M - NZYDNA Ladder Marker III (NZYTech); Lane 1 – PSUBL. B: Lane M – NZYDNA Ladder Marker III (NZYTech); Lane 1 – PSUBQ.

3. Molecular characterization of the sequenced results

Assembly of the final contig from the overlapping of the sequenced DNA segments was achieved using BioEdit and MEGA software. This sequence was compared to an available 8044 bp swine FASN sequence with the reference number NM_001099930.1 present on NCBI database and covered from 4903-7489 bp (illustration 34). The complete sequence of each successfully sequenced amplicon can be found in appendix II.

	4910	4920	4930	4940	4950
Final Contig				
Sequence NM_001099930.1	CAGCCACCTGGGAGGTGCCCTCCACCTGGACCCCTGGAGGAGGCAGCGTC				
	4960	4970	4980	4990	5000
Final Contig				
Sequence NM_001099930.1	GGTGCCCATCGTCTACACGACGGCCTACTACTCGCTGGTGGTGCGAGGGC				
	5010	5020	5030	5040	5050
Final Contig				
Sequence NM_001099930.1	GCATGCAGCCCGGGGAGTCGGTGCTCATCCACTCGGGCTCGGGCGGCGTG				
	5060	5070	5080	5090	5100
Final Contig				
Sequence NM_001099930.1	GGCCAGGCGGCCATCGCCATCGCCCTCAGCCGGGGCTGCCGCGTCTTCAC				
	5110	5120	5130	5140	5150
Final Contig				
Sequence NM_001099930.1	CACCGTGGGGTCGGCCGAGAAAGCGGGCGTACCTCCAGGCCAGGTTCCCCC				
	5160	5170	5180	5190	5200
Final Contig				
Sequence NM_001099930.1	AGCTCGACGAGACCTGCTTCGCCAACTCCC GCGACACGTCCCTTTGAGCAG				
	5210	5220	5230	5240	5250
Final Contig				
Sequence NM_001099930.1	CAGCTGCTGCGGCACACGCGCGGGGAGGGTGTCGACCTGGTCCTGAATC				
	5260	5270	5280	5290	5300
Final Contig				
Sequence NM_001099930.1	CCTGGCGGAAGAGAAAGCTGCAGGCCAGCGTGCGGTGCTGGCCAGCAGC				
	5310	5320	5330	5340	5350
Final Contig				
Sequence NM_001099930.1	GCCGCTTCTCGGAAATCGGCAAAATTCGACCTTTCCAAACAACACGCCCTG				
	5360	5370	5380	5390	5400
Final Contig				
Sequence NM_001099930.1	GGCATGGCCGTCTTCTGAAGAATGTGACCTTCCACGGGATCCTGCTGGA				
	5410	5420	5430	5440	5450
Final Contig				
Sequence NM_001099930.1	CTCGCTCTTTGAGGAGGGCGGCGCACCTGGCAGGAGGTGTCGGAGCTGC				
	5460	5470	5480	5490	5500
Final Contig				
Sequence NM_001099930.1	TGAGGCGGGCATCCAGGAGGGCGTGGTGTAGCCGCTCAAGTGCAACGTG				
	5510	5520	5530	5540	5550
Final Contig				
Sequence NM_001099930.1	TTCCCCAGGACCAAGGTGGAGGCCCTTCCGCTACATGGCCAGGGCAA				
	5560	5570	5580	5590	5600
Final Contig				
Sequence NM_001099930.1	GCACATAGGCAAAGTGGTCAATCCAGGTGCCGAGGAGGAGCAGGGGCCGG				
	5610	5620	5630	5640	5650
Final Contig				
Sequence NM_001099930.1	CGCCGCGCGGGCTGCCGCCATCGCATTTGACCGGCTTGTCCAAGACCTTC				

	5660	5670	5680	5690	5700
Final Contig				
Sequence NM_001099930.1	TGCCCCCCCCACAAGAGCTACGTGTCATCACCGGGGGCCTGGGCGGCCTTCGG				
				
Final Contig	5710	5720	5730	5740	5750
Sequence NM_001099930.1	CCTGCAGCTGGCGCAGTGGCTCCGGCTGCGAGGGGCCAGAGCTGGTGC				
				
Final Contig	5760	5770	5780	5790	5800
Sequence NM_001099930.1	TCACTTCCCGCTCGGGCATCCGCACAGGCTACCAGGCCAGGCAGGTCCGA				
				
Final Contig	5810	5820	5830	5840	5850
Sequence NM_001099930.1	GAGTGGAGACGCCAGGGCCTCCAGGTCTTGTTGCCACCAGCAACGCCAG				
				
Final Contig	5860	5870	5880	5890	5900
Sequence NM_001099930.1	CTCGCTGGACGGGCCTCGGAGCCTCATCAGCTGAGGCCACACAGCTTGGG				
				
Final Contig	5910	5920	5930	5940	5950
Sequence NM_001099930.1	CCCTGGGAGGCGTCTTCAACCTGGCCATGGTCTCTGAGAGACGCCGTGCTG				
				
Final Contig	5960	5970	5980	5990	6000
Sequence NM_001099930.1	GAGAACCAGACCCCGGAGTTCTTCCAGGACGTACGTAAGCCCAAGTACAG				
				
Final Contig	6010	6020	6030	6040	6050
Sequence NM_001099930.1	CGGCACCCGGAACCTGGACAGGGTGACCCGGGAGGCGTGTCCCGAGCTGG				
				
Final Contig	6060	6070	6080	6090	6100
Sequence NM_001099930.1	ACTACTTCTGTGATCTTCTCCTCCGTGAGCTCGGGCGCGGCAATGCCGGC				
				
Final Contig	6110	6120	6130	6140	6150
Sequence NM_001099930.1	CAGGCCAACTACGGCTTCGCCAACTCTGCCATGGAGCGCATCTGCGAGAA				
				
Final Contig	6160	6170	6180	6190	6200
Sequence NM_001099930.1	GCGCCGGCACGACGGGCTCCAGGCCTCGCGGTGCAGTGGGTGCGATCG				
				
Final Contig	6210	6220	6230	6240	6250
Sequence NM_001099930.1	GCGACGTGGGCGTGTCTCCCTGGAGACCATGGGCACCAACGACACGGTTCATC				
				
Final Contig	6260	6270	6280	6290	6300
Sequence NM_001099930.1	GGCGGGGACGCTGCCCCAGCGCATCGCCTCTGCTGGAGGTGCTGGATCT				
				
Final Contig	6310	6320	6330	6340	6350
Sequence NM_001099930.1	CTTCCTGAGCCAGCCCCACCCCGTCTTGAGCAGCTTCGTCTTGGCTGAGA				
				
Final Contig	6360	6370	6380	6390	6400
Sequence NM_001099930.1	AGAAGGCTGCCGCCCCCAGGGACGGCAGCAGCCAGAGGACCTGGTCAAG				
				

[illegible]

7160 7170 7180 7190 7200

Final Contig
Sequence NM_001099930.1

7210 7220 7230 7240 7250

Final Contig
Sequence NM_001099930.1

7260 7270 7280 7290 7300

Final Contig
Sequence NM_001099930.1

7310 7320 7330 7340 7350

Final Contig
Sequence NM_001099930.1

7360 7370 7380 7390 7400

Final Contig
Sequence NM_001099930.1

7410 7420 7430 7440 7450

Final Contig
Sequence NM_001099930.1

7460 7470 7480

Final Contig
Sequence NM_001099930.1

Illustration 34. Nucleotide sequence alignment of total sequenced product with swine FASN sequence NM_001099930.1.

The three previously displayed nucleotide differences reflect in two changes of amino acids in the translated sequence (an asparagine for a histidine and a leucine for a proline) (illustration 35).

Final_Contig
Sequence NM_001099930.1

Final_Contig
Sequence NM_001099930.1

Final_Contig
Sequence NM_001099930.1

Final_Contig
Sequence NM_001099930.1




Illustration 35. Protein sequence alignment of total sequenced product with swine FASN sequence NM_001099930.1.

V. DISCUSSION

Knowledge on the genetic background of fat tissue accumulation is of great importance in livestock production and as well as in biomedical research.

No references were found in current literature about *Sus mediterraneus* FASN specific primer sequences. Meanwhile, from the five pairs *Sus scrofa* FASN specific primer sequences previously described and fully tested in this work, only the product obtained from the use of two pairs (FASN39-FW/FASN39-RV and FASN40-FW/FASN40-RV) (Kim et al., 2011) have been successfully amplified and sequenced. The other ones, although submitted to different conditions (see 4.3 from chapter III) haven't given products successfully amplified and/or sequenced. Therefore, this work is based on the amplicons obtained with the 2 pairs of primers above mentioned and with other 4 pairs, from the 9 pairs designed and tested by the author.

Several FASN polymorphisms described in literature in cattle have been found associated with meat FA composition (Bhuiyan et al., 2009; Oztabak et al., 2014; Zhang et al., 2008). Furthermore, some of them have been assigned to the KR and TE domains. In humans, some reported FASN SNPs have been related with higher BMI, increased risk for developing prostate cancer and associated with dietary fat intakes (Bouchard-Mercier et al., 2012; Nguyen et al., 2010).

In swine FASN, some SNPs have already been described in breeds other than the AL/Iberian pig, most of them related to meat quality and FA composition (Kim et al., 2011; Munoz et al., 2007).

Our results on a partial sequence of the AL fatty acid synthase gene have shown three main exonic polymorphisms, two of them missense and one silent/synonymous (table 4).

Table 4. Characterization of the identified polymorphisms. Nomenclature of mutations follows Ogino et al. (2007)

DNA sequence change	Type of mutation	Amino acid change (three-letter code)	FASN site of mutation (exon)
c.6361C>T	synonymous	-	38
c.6632C>A	Non-synonymous	p.His2207Asn	39
c.6693C>T	Non-synonymous	p.Pro2227Leu	40

At the nucleotide position 6361, a cytosine was substituted by a thymine with no further consequences on the translated triplet (alanine, GCC > GCT). As this mutation does not conduce to an amino acid change, it is designated by synonymous single nucleotide polymorphism (sSNP).

At the nucleotide position 6632, a cytosine was substituted by an adenine, conducting to an alteration on the amino acid residue synthesized, from histidine (CAC) to asparagine (AAC) which is therefore named a non-synonymous single nucleotide polymorphism (nsSNP).

Finally, at the nucleotide position 6693, a cytosine was substituted by a thymine conducting to an nsSNP, because it modifies the translated sequence, a proline (CCC) for a leucine (CTC).

The structure of ACP and TE domains are not yet entirely resolved in the porcine FASN (Maier, 2008). Both nsSNPs identified in this work are located in this non determined coding region of the AL FASN gene. Nevertheless, c.6632C>A (His-Asn) is a polymorphism that has already been identified in other studies with *Sus scrofa* (accession number XP_003482986.2) although the origin of the biological material is not mentioned (tissue type and animal breed) and it has no publication associated to it.

Similarity coefficients between the sequenced AL FASN and the database record NM_001099930.1 (*Sus scrofa*) confirm that they are almost identical whether in terms of nucleotides (99,99%) or at the protein level (99,99%).

The AL FASN exonic sequence presented in this study covers part of the ER domain (4904 - 5575), part the KR domain (<5639 - 6349) and part of the TE domain (6740 - 7489). Additionally, this sequence covers the coding region of the phosphopantetheine attachment site (6359 - >6553), the short chain dehydrogenase region (5714 - 6172), several putative NADP binding sites, active sites and several NAD(P) binding sites. These regions have found to be highly conservative between AL and *Sus scrofa*. Estimate locations of the different regions were obtained from the reference sequence NM_001099930.1.

Sequence data obtained with this work were already deposited on the NCBI GenBank database under the accession number KM658506.

The KR domain is responsible for the first reduction in the FA synthesis cycle. In the presence of NADPH, it catalyzes the reduction of acetoacetyl ACP to D-3-hydroxybutyryl ACP. After dehydration, the ER domain catalyzes the second reduction step of the acyl intermediate trans- Δ^2 -enoyl ACP into butyryl ACP, again with NADPH as electron donor (Berg et al., 2012).

During FA synthesis, the growing acyl intermediate is attached to an ACP throughout the elongation cycles until a 16 carbon chain lenght FA is released by a TE. This domain leads to the release of palmitate by the hydrolysis of the acyl-S-

phosphopantetheine thioester bound to the preceding ACP domain (Chakravarty et al., 2004).

TE domains are important regions in the FASN gene because they are potential substrates for elongation and denaturation that are responsible for length determination of the FASN gene. The structure of the human TE domain is already determined. It is comprised of two dissimilar subdomains, A and B. The structure has a hydrophobic groove with a distal pocket at the interface of the two subdomains, constituting the candidate substrate binding site. As the TE domain ensures that the majority of FAS product is palmitate (C16), variations within this domain coding sequence may influence the structure of substrate-binding site and affect the specific activity towards acyl ACP intermediates (Chakravarty et al., 2004; Maharani et al., 2011; Zhang et al., 2008).

Moreover, Zhang et al. (2008) identified, in bovines, two novel nonsynonymous mutations in the TE domain of FAS, g.18663T>C and g.18727C>T, which were associated with decreased amounts of unsaturated fatty acids. These TE polymorphisms might be related to the ones described hereby, though complementary studies are required to analyze such hypothesis.

ACP is a single polypeptide constituted of 77 residues with scarce publication related to it about polymorphisms among different species (Berg et al., 2012).

A recent genome study on Mangalica (Molnar et al., 2014), an obese local pig of Hungary, concluded that local/rare breeds could be a rich source of sequence variations not present in industrial/lean breeds. Therefore, identified variations within such breeds, as the AL, might be useful resource for future studies of pig's traits.

VI. CONCLUSIONS AND FUTURE PERSPECTIVES

Three polymorphisms were identified in about 33% of the total gene sequence. Two of these SNP's, namely c.6632C>A and c.6693C>T, lead to changes in the translated triplet (missense mutations) and are located somewhere around the acyl carrier protein and thioesterase FASN domains, locations not yet fully understood in swine, particularly in terms of structure. This fact suggests that further complementary studies are required in order to investigate possible consequences induced by these polymorphisms and relate them with previously described ones on other swine breeds and/or species.

On the other hand, it is necessary to complete the genotyping of the FASN in the AL breed since the discovery of more FASN polymorphisms on the remaining coding sequence that may provide useful information, is a solid possibility.

REFERENCES

- Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic acids research* 25, 3389-3402.
- Arner, P. (2005). Resistin: yet another adipokine tells us that men are not mice. *Diabetologia* 48, 2203-2205.
- Berg, J.M., Tymoczko, J.L., and Stryer, L. (2012). *Biochemistry*. (Basingstoke: W. H. Freeman).
- Berndt, J., Kovacs, P., Ruschke, K., Kloting, N., Fasshauer, M., Schon, M.R., Korner, A., Stumvoll, M., and Bluher, M. (2007). Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes. *Diabetologia* 50, 1472-1480.
- Bhuiyan, M.S.A., Yu, S.L., Jeon, J.T., Yoon, D., Cho, Y.M., Park, E.W., Kim, N.K., Kim, K.S., and Lee, J.H. (2009). DNA Polymorphisms in SREBF1 and FASN Genes Affect Fatty Acid Composition in Korean Cattle (Hanwoo). *Asian-Aust. J. Anim. Sci.* 22, 765-773.
- Bjorntorp, P., Bergman, H., and Varnauskas, E. (1969). Plasma free fatty acid turnover rate in obesity. *Acta medica Scandinavica* 185, 351-356.
- Bouchard-Mercier, A., Paradis, A.M., Perusse, L., and Vohl, M.C. (2012). Associations between polymorphisms in genes involved in fatty acid metabolism and dietary fat intakes. *Journal of nutrigenetics and nutrigenomics* 5, 1-12.
- Brennan, A.M., and Mantzoros, C.S. (2006). Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. *Nature clinical practice. Endocrinology & metabolism* 2, 318-327.
- Brisbin, J.I.L., and Sturek, M.S. (2009). The Pigs of Ossabaw Island: A Case Study of the Application of Long-term Data in Management Plan Development. In *Wild Pigs: Biology, Damage, Control Techniques and Management*. J.J.B. Mayer, I. L., ed. (Savannah River National Laboratory, Aiken, SC).
- Brown, T.A. (2010). *Gene cloning and DNA analysis : an introduction*. (Oxford ; Hoboken, NJ: Wiley-Blackwell).
- Bruun, J.M., Lihn, A.S., Verdich, C., Pedersen, S.B., Toubro, S., Astrup, A., and Richelsen, B. (2003). Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. *American journal of physiology. Endocrinology and metabolism* 285, E527-533.
- Canon, J., Garcia, D., Delgado, J.V., Dunner, S., Telo da Gama, L., Landi, V., Martin-Burriel, I., Martinez, A., Penedo, C., Rodellar, C., et al. (2011). Relative breed contributions to neutral genetic diversity of a comprehensive representation of Iberian native cattle. *Animal : an international journal of animal bioscience* 5, 1323-1334.
- Chait, A., and Kim, F. (2010). Saturated fatty acids and inflammation: who pays the toll? *Arteriosclerosis, thrombosis, and vascular biology* 30, 692-693.
- Chakravarty, B., Gu, Z., Chirala, S.S., Wakil, S.J., and Quiocho, F.A. (2004). Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain. *Proceedings of the National Academy of Sciences of the United States of America* 101, 15567-15572.

- Chilliard, Y. (1993). Dietary Fat and Adipose Tissue Metabolism in Ruminants, Pigs, and Rodents: A Review. *J Dairy Sci* 76, 3897-3931.
- Cirera, S., Jensen, M.S., Elbrond, V.S., Moesgaard, S.G., Christoffersen, B.O., Kadarmideen, H.N., Skovgaard, K., Bruun, C.V., Karlskov-Mortensen, P., Jorgensen, C.B., et al. (2014). Expression studies of six human obesity-related genes in seven tissues from divergent pig breeds. *Animal genetics* 45, 59-66.
- Clop, A., Ovilo, C., Perez-Enciso, M., Cercos, A., Tomas, A., Fernandez, A., Coll, A., Folch, J.M., Barragan, C., Diaz, I., et al. (2003). Detection of QTL affecting fatty acid composition in the pig. *Mammalian genome : official journal of the International Mammalian Genome Society* 14, 650-656.
- Corominas, J., Ramayo-Caldas, Y., Puig-Oliveras, A., Estelle, J., Castello, A., Alves, E., Pena, R.N., Ballester, M., and Folch, J.M. (2013). Analysis of porcine adipose tissue transcriptome reveals differences in de novo fatty acid synthesis in pigs with divergent muscle fatty acid composition. *BMC genomics* 14, 843.
- Daza, A., Lopez-Bote, C., Rey, A., and Olivares, A. (2006). Effect of age at the beginning of the free-range fattening period on growth and carcass and fat quality in Iberian pigs. *Archives of animal nutrition* 60, 317-324.
- Daza, A., Rey, A.I., Isabel, B., and Lopez-Bote, C.J. (2005). Effect of dietary vitamin E and partial replacement of poly- with monounsaturated fat on fatty acid patterns of backfat and intramuscular fat in heavy pigs (Iberian x Duroc). *Journal of animal physiology and animal nutrition* 89, 20-28.
- Estévez, M., Morcuende, D., and Cava, R. (2006). Extensively reared Iberian pigs versus intensively reared white pigs for the manufacture of frankfurters. *Meat science* 72, 356-364.
- Fabuel, E., Barragan, C., Silio, L., Rodriguez, M.C., and Toro, M.A. (2004). Analysis of genetic diversity and conservation priorities in Iberian pigs based on microsatellite markers. *Heredity* 93, 104-113.
- FAO (2013). *FAO Statistical Yearbook 2012*.
- FAO Food and Agricultural Organization of the United Nations. (2013a). *FAO Statistical Yearbook 2012. Europe and Central Asia Food and agriculture*. (Rome: FAO).
- FAO Food and Agricultural Organization of the United Nations. (2013b). *The state of food and agriculture 2013: food systems for better nutrition*. (Rome: Food and Agriculture Organization of the United Nations), p. electronic text.
- Faris, R.J., Boddicker, R.L., Walker-Daniels, J., Li, J., Jones, D.E., and Spurlock, M.E. (2012). Inflammation in response to n3 fatty acids in a porcine obesity model. *Comparative medicine* 62, 495-503.
- Freitas, A.B., Neves, J., Charneca, R., J., T.N., and Martins, J.M. (2007). Influence of slaughter weight on growth and carcass characteristics of Alentejano pigs. In *5th International Symposium on the Mediterranean Pig (Zaragoza)*, pp. 109-113.
- Freitas, A.B., Neves, J., Nunes, J., and M., M.J. (2006). O sistema agro-silvo-pastoril da raça suína alentejana. In *IV Congreso Latinoamericano de Agroforestería para la Producción Pecuaria Sostenible*.
- Frohman, M.A., Dush, M.K., and Martin, G.R. (1988). Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. *Proceedings of the National Academy of Sciences of the United States of America* 85, 8998-9002.

- Gnoni, G.V., Priore, P., Geelen, M.J., and Siculella, L. (2009). The mitochondrial citrate carrier: metabolic role and regulation of its activity and expression. *IUBMB life* 61, 987-994.
- Gonzalez-Anover, P., Encinas, T., Gomez-Izquierdo, E., Sanz, E., Letelier, C.A., Torres-Rovira, L., Pallares, P., Sanchez-Sanchez, R., and Gonzalez-Bulnes, A. (2010). Advanced onset of puberty in gilts of thrifty genotype (Iberian pig). *Reproduction in domestic animals = Zuchthygiene* 45, 1003-1007.
- Groenen, M.A., Archibald, A.L., Uenishi, H., Tuggle, C.K., Takeuchi, Y., Rothschild, M.F., Rogel-Gaillard, C., Park, C., Milan, D., Megens, H.J., et al. (2012). Analyses of pig genomes provide insight into porcine demography and evolution. *Nature* 491, 393-398.
- Haffner, S.M., Lehto, S., Ronnema, T., Pyorala, K., and Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 339, 229-234.
- Hall, T.A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. In *Nucleic Acids Symposium Series*, pp. 95-98.
- Hamamdžić, D., and Wilensky, R.L. (2013). Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia. *Journal of diabetes research* 2013, 761415.
- Harford, K.A., Reynolds, C.M., McGillicuddy, F.C., and Roche, H.M. (2011). Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. *The Proceedings of the Nutrition Society* 70, 408-417.
- Harms, M., and Seale, P. (2013). Brown and beige fat: development, function and therapeutic potential. *Nature medicine* 19, 1252-1263.
- Hood, R.L., and Allen, C.E. (1973). Lipogenic enzyme activity in adipose tissue during the growth of swine with different propensities to fatten. *The Journal of nutrition* 103, 353-362.
- Hopperton, K. (2012). The Role of Fatty Acid Synthase Over-Expression in Human Breast Cancer. In *Graduate Department of Nutritional Sciences (University of Toronto)*, p. 82.
- Huang, Q.C., Xu, Z.R., Han, X.Y., and Li, W.F. (2007). Effect of dietary betaine supplementation on lipogenic enzyme activities and fatty acid synthase mRNA expression in finishing pigs. *Animal Feed Science and Technology* 140, 365-375.
- Hussain, G., Schmitt, F., Loeffler, J.P., and Gonzalez de Aguilar, J.L. (2013). Fattening the brain: a brief of recent research. *Frontiers in cellular neuroscience* 7, 144.
- Jayakumar, A., Tai, M.H., Huang, W.Y., al-Feel, W., Hsu, M., Abu-Elheiga, L., Chirala, S.S., and Wakil, S.J. (1995). Human fatty acid synthase: properties and molecular cloning. *Proceedings of the National Academy of Sciences of the United States of America* 92, 8695-8699.
- Kim, S.W., Il Choi, Y., Choi, J.S., Kim, J.J., Choi, B.H., Kim, T.H., and Kim, K.S. (2011). Porcine Fatty Acid Synthase Gene Polymorphisms Are Associated with Meat Quality and Fatty Acid Composition. *Korean J Food Sci An* 31, 356-365.
- Kimball, J.W. (1994). *Biology*. (Dubuque ; Oxford: Wm. C. Brown).
- Klug, W.S. (2012). *Concepts of genetics*. (Boston, MA: Pearson Education).
- Lehninger, A.L., Nelson, D.L., and Cox, M.M. (2008). *Lehninger principles of biochemistry*. (New York: W.H. Freeman).
- Liu, H. (2008). Fatty acid synthase, a novel target for the treatment of drug resistant breast cancers (Indiana University), p. 129.

- Loftus, T.M., Jaworsky, D.E., Frehywot, G.L., Townsend, C.A., Ronnett, G.V., Lane, M.D., and Kuhajda, F.P. (2000). Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. *Science (New York, N.Y.)* 288, 2379-2381.
- Lopez-Bote, C.J. (1998). Sustained utilization of the Iberian pig breed. *Meat science* 49, *Supplement 1*, S17-S27.
- Lubis, A.R., Widia, F., Soegondo, S., and Setiawati, A. (2008). The role of SOCS-3 protein in leptin resistance and obesity. *Acta medica Indonesiana* 40, 89-95.
- Lunney, J.K. (2007). Advances in swine biomedical model genomics. *International journal of biological sciences* 3, 179-184.
- Maharani, D., Jo, C., Jeon, J.T., and Lee, J.H. (2011). Quantitative Trait Loci and Candidate Genes Affecting Fatty Acid Composition in Cattle and Pig. *Korean J. Food Sci. Ani. Resour* 31, 325-338.
- Maharani, D., Jung, Y.-k., Jo, C., Jung, W.-Y., Nam, K.-C., Seo, K.-S., Lee, S.-H., and Lee, J.-H. (2012). Evaluation of Three Candidate Genes Affecting Fatty Acid Composition in Pigs. *Korean J Food Sci An* 32, 6-12.
- Maier, T., Jenni, S., and Ban, N. (2006). Architecture of mammalian fatty acid synthase at 4.5 Å resolution. *Science (New York, N.Y.)* 311, 1258-1262.
- Maier, T., Leibundgut, M., and Ban, N. (2008). The crystal structure of a mammalian fatty acid synthase. *Science (New York, N.Y.)* 321, 1315-1322.
- Martins, J.M., Neves, J.A., Freitas, A., and Tirapicos, J.L. (2012). Effect of long-term betaine supplementation on chemical and physical characteristics of three muscles from the Alentejano pig. *Journal of the science of food and agriculture* 92, 2122-2127.
- Matos, C.A.P. (2000). Recursos genéticos animais e sistemas de exploração tradicionais em Portugal. *Archivos de zootecnia* 49, 363-383.
- Meurens, F., Summerfield, A., Nauwynck, H., Saif, L., and Gerdts, V. (2012). The pig: a model for human infectious diseases. *Trends in microbiology* 20, 50-57.
- Molnar, J., Nagy, T., Steger, V., Toth, G., Marincs, F., and Barta, E. (2014). Genome sequencing and analysis of Mangalica, a fatty local pig of Hungary. *BMC genomics* 15, 761.
- Munoz, G., Alves, E., Fernandez, A., Ovilo, C., Barragan, C., Estelle, J., Quintanilla, R., Folch, J.M., Silio, L., Rodriguez, M.C., et al. (2007). QTL detection on porcine chromosome 12 for fatty-acid composition and association analyses of the fatty acid synthase, gastric inhibitory polypeptide and acetyl-coenzyme A carboxylase alpha genes. *Animal genetics* 38, 639-646.
- Munoz, G., Ovilo, C., Noguera, J.L., Sanchez, A., Rodriguez, C., and Silio, L. (2003). Assignment of the fatty acid synthase (FASN) gene to pig chromosome 12 by physical and linkage mapping. *Animal genetics* 34, 234-235.
- Munoz, G., Ovilo, C., Silio, L., Tomas, A., Noguera, J.L., and Rodriguez, M.C. (2009). Single- and joint-population analyses of two experimental pig crosses to confirm quantitative trait loci on *Sus scrofa* chromosome 6 and leptin receptor effects on fatness and growth traits. *Journal of animal science* 87, 459-468.
- Myers, M.G., Cowley, M.A., and Munzberg, H. (2008). Mechanisms of leptin action and leptin resistance. *Annual review of physiology* 70, 537-556.
- Neel, J.V. (1962). Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? *American journal of human genetics* 14, 353-362.
- Nguyen, P.L., Ma, J., Chavarro, J.E., Freedman, M.L., Lis, R., Fedele, G., Fiore, C., Qiu, W., Fiorentino, M., Finn, S., et al. (2010). Fatty acid synthase polymorphisms, tumor expression,

body mass index, prostate cancer risk, and survival. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 28, 3958-3964.

Nunes, J.L.T. (1993). Contributo para a reintegração do porco alentejano no montado. (University of Évora), p. 276.

Ogino, S., Gulley, M.L., den Dunnen, J.T., Wilson, R.B., Association for Molecular Pathology, T., and Education, C. (2007). Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. *The Journal of molecular diagnostics : JMD* 9, 1-6.

Ovilo, C., Fernandez, A., Noguera, J.L., Barragan, C., Leton, R., Rodriguez, C., Mercade, A., Alves, E., Folch, J.M., Varona, L., et al. (2005). Fine mapping of porcine chromosome 6 QTL and LEPR effects on body composition in multiple generations of an Iberian by Landrace intercross. *Genetical research* 85, 57-67.

Oztabak, K., Gursel, F.E., Akis, I., Ates, A., Yardibi, H., and Turkay, G. (2014). FASN gene polymorphism in indigenous cattle breeds of Turkey. *Folia biologica* 62, 29-35.

Pugliese, C., and Sirtori, F. (2012). Quality of meat and meat products produced from southern European pig breeds. *Meat science* 90, 511-518.

Pugliese, C., Sirtori, F., and Franci, O. (2013). Feeding strategies for local breeds in view of product quality. In 8th International Symposium on the Mediterranean Pig (Ljubljana, Slovenia), pp. 69-75.

Qatanani, M., and Lazar, M.A. (2007). Mechanisms of obesity-associated insulin resistance: many choices on the menu. *Genes & development* 21, 1443-1455.

Ren, J., Knorr, C., Huang, L., and Brenig, B. (2004). Isolation and molecular characterization of the porcine stearoyl-CoA desaturase gene. *Gene* 340, 19-30.

Rothschild, M.F., and Ruvinsky, A. (2011). Pigs as a Model for Biomedical Sciences. In *The genetics of the pig* (Wallingford: Cabi).

Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). *Molecular cloning a laboratory manual*. (Cold Spring Harbor: Cold Spring Harbor laboratory press).

Schook, L.B., Beever, J.E., Rogers, J., Humphray, S., Archibald, A., Chardon, P., Milan, D., Rohrer, G., and Eversole, K. (2005). Swine Genome Sequencing Consortium (SGSC): a strategic roadmap for sequencing the pig genome. *Comparative and functional genomics* 6, 251-255.

Semenkovich, C.F. (1997). Regulation of fatty acid synthase (FAS). *Progress in lipid research* 36, 43-53.

Spurlock, M.E., and Gabler, N.K. (2008). The development of porcine models of obesity and the metabolic syndrome. *The Journal of nutrition* 138, 397-402.

Strable, M.S., and Ntambi, J.M. (2010). Genetic control of de novo lipogenesis: role in diet-induced obesity. *Critical reviews in biochemistry and molecular biology* 45, 199-214.

Switonski, M., Stachowiak, M., Cieslak, J., Bartz, M., and Grzes, M. (2010). Genetics of fat tissue accumulation in pigs: a comparative approach. *Journal of applied genetics* 51, 153-168.

Teixeira, A., and Rodrigues, S. (2013). Pork Meat Quality of Preto Alentejano and Commercial Largewhite Landrace Cross. *Journal of Integrative Agriculture* 12(11), 1961-1971.

Toedebusch, R.G., Roberts, M.D., Wells, K.D., Company, J.M., Kanosky, K.M., Padilla, J., Jenkins, N.T., Perfield, J.W., 2nd, Ibdah, J.A., Booth, F.W., et al. (2014). Unique transcriptomic signature of omental adipose tissue in Ossabaw swine: a model of childhood obesity. *Physiological genomics* 46, 362-375.

- Torres-Rovira, L., Astiz, S., Caro, A., Lopez-Bote, C., Ovilo, C., Pallares, P., Perez-Solana, M.L., Sanchez-Sanchez, R., and Gonzalez-Bulnes, A. (2012). Diet-induced swine model with obesity/leptin resistance for the study of metabolic syndrome and type 2 diabetes. *TheScientificWorldJournal* 2012, 510149.
- Tvrzicka, E., Kremmyda, L.-S., Stankova, B., and Zak, A. (2011). Fatty acids as biocompounds: Their role in human metabolism, health and disease – a review. Part 1: Classification, dietary sources and biological functions. 117–130.
- Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B.C., Remm, M., and Rozen, S.G. (2012). Primer3--new capabilities and interfaces. *Nucleic acids research* 40, e115.
- Vance, D.E., and Vance, J.E. (2008). *Biochemistry of lipids, lipoproteins and membranes*. (Amsterdam: Elsevier,).
- Walters, E.M., Wolf, E., Whyte, J.J., Mao, J., Renner, S., Nagashima, H., Kobayashi, E., Zhao, J., Wells, K.D., Critser, J.K., et al. (2012). Completion of the swine genome will simplify the production of swine as a large animal biomedical model. *BMC medical genomics* 5, 55.
- Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. *The Journal of clinical investigation* 112, 1796-1808.
- Whyte, J.J., and Prather, R.S. (2011). Genetic modifications of pigs for medicine and agriculture. *Molecular reproduction and development* 78, 879-891.
- Wood, J.D., Enser, M., Fisher, A.V., Nute, G.R., Sheard, P.R., Richardson, R.I., Hughes, S.I., and Whittington, F.M. (2008). Fat deposition, fatty acid composition and meat quality: A review. *Meat science* 78, 343-358.
- Wu, X., Motoshima, H., Mahadev, K., Stalker, T.J., Scalia, R., and Goldstein, B.J. (2003). Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. *Diabetes* 52, 1355-1363.
- Wulster-Radcliffe, M.C., Ajuwon, K.M., Wang, J., Christian, J.A., and Spurlock, M.E. (2004). Adiponectin differentially regulates cytokines in porcine macrophages. *Biochemical and biophysical research communications* 316, 924-929.
- Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *The Journal of clinical investigation* 112, 1821-1830.
- Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A.J., Tomiyama, Y., et al. (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. *Blood* 96, 1723-1732.
- Zhang, S., Knight, T.J., Reecy, J.M., and Beitz, D.C. (2008). DNA polymorphisms in bovine fatty acid synthase are associated with beef fatty acid composition. *Animal genetics* 39, 62-70.

APPENDIX I – COMPLETE LIST OF TESTED PRIMERS

Primer Designation	Gene Location (bp)	5'→ 3' Primer Sequence	Sense/ Antisense
FAS S	119-139	GACGACAGGCGGTGGAAGGCG	Sense
FAS AS	749-771	GTGTTCGTGCCCCGCATTGAGGAT	Antisense
FAS T FW	1216-1236	CGTCATCCTTCAGCCCAACTC	Sense
FAS T RV	2578-2599	ATAGACGGCGACAGAGGAGCAG	Antisense
FAS P FW	2358-2375	TCCCGCTGATGAAGAAGG	Sense
FAS P RV	4084-4101	GTGAGGAAGCCGACCATC	Antisense
FAS Y FW	3735-3754	AGATGAAGGTGGTGGAGGTG	Sense
FAS Y RV	5549-5568	GGCAAGCACATAGGCAAAGT	Antisense
FAS X FW	5463-5479	GCATCCAGGAGGGCGTG	Sense
FAS X RV	6615-6631	GGATGTGGGAGTCGCCG	Antisense
FASN exon39-FW	6615-6631	CGGCGACTCCACATCC	Sense
FASN exon39-RV	7025-7045	GAAGGTGTGTGAGCCGTCGAA	Antisense
FASN exon40-FW	6908-6928	CCCGAGGGGCTTACCGCATC	Sense
FASN exon40-RV	7268-7285	GAAGGAGCGAGCGGCGAA	Antisense
FAS F FW	7015-7035	CCTCTTCTGTTCGACGGCTC	Sense
FAS F RV	7490-7511	TGTGGATGATGCTGAGGATGGA	Antisense
FASN1 FW	88-115	CCTCATCGGCGGTGTGGA	Sense
FASN1 RV	442-465	CTGAAGTCGAAGAAGAAGGAGAGC	Antisense
FASN2 FW	435-455	CCAACCGGCTCTCCTTCTTCT	Sense
FASN2 RV	873-894	CCGTGGGCTTCGATGTATTCAA	Antisense
FAS L FW	5393-5415	ATCCTGCTGGACTCGCTCTTTGA	Sense
FAS L RV	6158-6175	TGGGAGCCCGTCGTGCCG	Antisense
FAS Q FW	6108-6130	CCAACCTACGGCTTCGCCAACTCT	Sense
FAS Q RV	6746-6767	CGATGGGGTGGACCAGGAACAG	Antisense
FAS D FW	4881-4902	CCACCTCTGTTCTGCTGCTTCA	Sense
FAS D RV	5546-5565	TTGCCTATGTGCTTGCCCTG	Antisense
FAS H FW	4092-4114	GCTTCCTCACCTCCCCTGAACAA	Sense
FAS H RV	5020-5040	CCCGAGTGGATGAGCACCGAC	Antisense
FAS RACE 3'	7452-7477	CACCGCACGCTGCTGGAGGGC	Sense
Oligo d(T) anchor NotI	-	AACCCGGCTCGAGCGGCCGCT ₁₈	-
Anchor T	-	AACCCGGCTCGAGCGGCCGC	-

APPENDIX II – FULL ALIGNMENT PRESENTATION OF EACH SEQUENCED DNA PORTION

Amplicon D:

```

      10      20      30      40      50
Final Contig Amplicon D
Sequence NM_001099930.1
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
CACGCCACCTGGGAGGTGCCCTCCACCTGGACCCTGGAGGAGGCAGCGTC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

      60      70      80      90     100
Final Contig Amplicon D
Sequence NM_001099930.1
GGTGGCCATCGTCTACACGACGGCCTACTACTCGCTGGTGGTGGAGGGC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     110     120     130     140     150
Final Contig Amplicon D
Sequence NM_001099930.1
GCATGCAGCCCGGGGAGTCGGTGCTCATCCACTCGGGCTCGGGCGGCGTG
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     160     170     180     190     200
Final Contig Amplicon D
Sequence NM_001099930.1
GGCCAGGCCGCCATCGCCATCGCCCTCAGCCGGGGCTGCCGCGTCTTCAC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     210     220     230     240     250
Final Contig Amplicon D
Sequence NM_001099930.1
CACCGTGGGTCGGCCGAGAAGCGGGCGTACCTCCAGGCCAGGTTCCCCC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     260     270     280     290     300
Final Contig Amplicon D
Sequence NM_001099930.1
AGCTCGACGAGACCTGCTTCGCCAATCCCCCGACACGTCTTTGAGCAG
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     310     320     330     340     350
Final Contig Amplicon D
Sequence NM_001099930.1
CACGTGCTGCGGCACACGGCCGGGAAGGGTCTCGACCTGGTCCTGAATC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     360     370     380     390     400
Final Contig Amplicon D
Sequence NM_001099930.1
CCTGGCGGAAGAGAACTGTCAGGCCAGCGTCGGGTCTTGGCCCGACAG
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     410     420     430     440     450
Final Contig Amplicon D
Sequence NM_001099930.1
GCCGCTTCTGGAAATCGGCAAAATTCGACCTTTCCAAACCAACGCCCCTG
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     460     470     480     490     500
Final Contig Amplicon D
Sequence NM_001099930.1
GGCATGGCCGTCTTCTGAAGAATGTGACCTTCCACGGGATCCTGCTGGA
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     510     520     530     540     550
Final Contig Amplicon D
Sequence NM_001099930.1
CTCGCTCTTTGAGGAGGGCGGCCACCTGGCAGGAGGTCTCGGAGCTGC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     560     570     580     590     600
Final Contig Amplicon D
Sequence NM_001099930.1
TGAAGGCGGGCATCCAGGAGGGCGTGGTGCAGCCGCTCAAGTGACCGTG
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

     610     620     630     640
Final Contig Amplicon D
Sequence NM_001099930.1
TTCCCCAGGACCAAGGTGGAGGCCGCTTCCGCTACATGGCC
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

```

Amplicon L:

```

      10      20      30      40      50
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L GGAGGCGGCGCCACCTGGCAGGAGGTGTCGGAGCTGCTGAAGCGGGCA
Sequence NM_001099930.1 .....

      60      70      80      90     100
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L TCCAGGAGGGCGTGGTGCAGCCGCTCAAGTGCACCGTGTTCCTCCAGGACC
Sequence NM_001099930.1 .....

     110     120     130     140     150
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L AAGGTGGAGGCGGCTTCCGCTACATGGCCCAGGGCAAGCACATAGGCAA
Sequence NM_001099930.1 .....

     160     170     180     190     200
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L AGTGGTTCATCCAGGTGCGCGAGGAGGAGCAGGGGCGGCGCCGCGCGGGC
Sequence NM_001099930.1 .....

     210     220     230     240     250
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L TGCCGCCCATCGCATTGACCGGCTTGTCCAAGACCCTCTGCCCCCCCCAC
Sequence NM_001099930.1 .....

     260     270     280     290     300
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L AAGAGCTACGTTCATCACCGGGGGCTGGGCGGCTTCGGCCTGCAGCTGGC
Sequence NM_001099930.1 .....

     310     320     330     340     350
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L GCAGTGGCTCCGGCTGCGAGGGGGCCAGAAGCTGGTGCTCACCTCCCGCT
Sequence NM_001099930.1 .....

     360     370     380     390     400
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L CGGGCAATCCGCACAGGCTACCAGGCCAGGCAGGTCCGAGAGTGGAGACGC
Sequence NM_001099930.1 .....

     410     420     430     440     450
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L CAGGGCGTCCAGGTCTTGGTGTCCACCAGCAACGCCAGCTCGCTGGACGG
Sequence NM_001099930.1 .....

     460     470     480     490     500
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L CGCTCGGAGCCTCATCACTGAGGCCACACAGCTTGGGCCCGTGGGAGGCG
Sequence NM_001099930.1 .....

     510     520     530     540     550
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L TCTTCAACCTGGCCATGGTCCTGAGAGACGCCGTGCTGGAGAACCAGACC
Sequence NM_001099930.1 .....

     560     570     580     590     600
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L CCGGAGTTCTTCCAGGACGTCAGTAAGCCCAGTACAGCGGCACCGCGAA
Sequence NM_001099930.1 .....

     610     620     630     640     650
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L CCTGGACAGGGTGACCCGGGAGGCGTGTCCCGAGCTGGACTACTTCTGTGA
Sequence NM_001099930.1 .....

     660     670     680     690     700
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L TCTTCTCCTCCGTGAGCTGCGGGCGGGCAATGCCGGCCAGGCCAACTAC
Sequence NM_001099930.1 .....

     710     720     730     740
...|...|...|...|...|...|...|...|...|...|
Final Contig Amplicon L GGCTTCGCCAACTCTGCCATGGAGCGCATCTGCGAGAAGCGC
Sequence NM_001099930.1 .....

```

Amplicon Q:

```

      10      20      30      40      50
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 GCCATGGAGCGCATCTGCGAGAAGCGCCGGCACGACGGGCTCCCAGGCCT
      60      70      80      90     100
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 CGCCGTGCAGTGGGGTGGGATCGGCGACGTGGGCGTCGTCCCTGGAGACCA
      110     120     130     140     150
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 TGGGCACCAACGACACGGTCATCGGCGGGACGCTGCCCCAGCGCATCGCC
      160     170     180     190     200
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 TCCTGCCTGGAGGTGCTGGATCTCTTCCTGAGCCAGCCCCACCCCTCCT
      210     220     230     240     250
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 GAGCAGCTTCGTCCCTGGCTGAGAAGAAGGCTGCCGCCCCAGGGACGGCA
      260     270     280     290     300
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 GCAGCCAGAAGGACCTGGTCAAGGCCGTGGCTCACATCCTGGGCATCCGG
      310     320     330     340     350
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 GACGTGGCCCTCCATCAATCCGGACAGCAGCTGGTGGACCTGGGCCCTGGA
      360     370     380     390     400
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 CTCGCTCATGGGCGTGGAGGTGCGCCAGATCTGGAGCGAGAGCACGACC
      410     420     430     440     450
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 TGGTGTCTGCCATGCGGGAGGTGCGGCAGCTCAGCCTCCGGAAGCTACAG
      460     470     480     490     500
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 GAACTCTCCTCGAAGACCAGCACGGACGCCGACCCGGCGACTCCCACATC
      510     520     530     540     550
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 CAACGAGGACAGCCCTGTGCGGCAGCAGGCAACGCTGAACCTGAGCACCC
      560     570     580     590     600
Final Contig Amplicon Q .....|.....|.....|.....|.....|
Sequence NM_001099930.1 TGCTGGTGAACCCCGAGGGCCCGACCTTGACGCGGCTCAACTCCGTGCAG
      610
Final Contig Amplicon Q .....|.....|
Sequence NM_001099930.1 AGCGCAGAGCGGCC

```

Amplicon exon39:

```

      10      20      30      40      50
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      AACGAGGACAGCCCTGTGCGGCAGCAGGCAACGCTGAACCTGAGCACCCCT
C.....

      60      70      80      90     100
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      GCTGGTGAACCTCGAGGGCCCGACCTTGACCGGGCTCAACTCCGTGCAGA
.....C.....

      110     120     130     140     150
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      GCGCAGAGCGGCCCTGTTCCTGGTCCACCCCATCGAGGGCTCCATCACC
.....

      160     170     180     190     200
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      GTGTTCCACGGCCTGGCCGCAAGCTCAGCATCCCCACCTACGGCCTGCA
.....

      210     220     230     240     250
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      GTGCACGGGAGCCGCCCGCTGGACAGCATCCAGAGCCTGGCCTCTACT
.....

      260     270     280     290     300
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      ACATCGAGTGCATCAGACAGGTGCAGCCCGAGGGGCCTTACCGCATCGCC
.....

      310     320     330     340     350
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      GGCTACTCTTACGGGCTGCGTGGCCTTCGAGATGTGCTCGCAGCTGCA
.....

      360     370     380     390
Final Contig Amplicon Exon39  ....|....|....|....|....|....|
Sequence NM_001099930.1      GGCCAGCAGAGCGCCACCCCGGGGAACCAAGCCTCTTCTTG
.....

```

Amplicon exon40:

```

      10      20      30      40      50
Final Contig Amplicon Exon40  ....|....|....|....|....|....|
Sequence NM_001099930.1      GCCGGCTACTCTTACGGGGCTGCGTGGCCTTCGAGATGTGCTCGCAGCT
.....

      60      70      80      90     100
Final Contig Amplicon Exon40  ....|....|....|....|....|....|
Sequence NM_001099930.1      GCAGGCCAGCAGAGGCCACCCCGGGAAACACAGCCTTTCCTGTTCG
.....

      110     120     130     140     150
Final Contig Amplicon Exon40  ....|....|....|....|....|....|
Sequence NM_001099930.1      ACGGCTCACACACCTTCGTGCTGGCCTACACGAGAGCGTCCGCGCTAAG
.....

      160     170     180     190     200
Final Contig Amplicon Exon40  ....|....|....|....|....|....|
Sequence NM_001099930.1      ATGACCCCGGCTGCGAGGCCGAGGCCGAGGCCAAGGCCATGTACTTCTT
.....

      210     220     230     240     250
Final Contig Amplicon Exon40  ....|....|....|....|....|....|
Sequence NM_001099930.1      CGTGAGCAGTTTACCGACATGGAGCAAGGCAAGGTGCTGGAGGCGCTGA
.....

```

```

                260       270       280       290       300
Final Contig Amplicon Exon40  TACCGCTCCAGGGCCTGGAGGCGCGCGTGGCGGCCACCGTGGACCTGATC
Sequence NM_001099930.1      .....

                310       320       330
Final Contig Amplicon Exon40  ACGCAGAGCCACGCGGGCCTGGACCGCCACGCCCTCAGC
Sequence NM_001099930.1      .....

```

Amplicon F:

```

                10       20       30       40       50
Final Contig Amplicon F      ACACACCTTCGTGCTGGCCTACACGCAGAGCGTCCGCGCTAAGATGACCC
Sequence NM_001099930.1      .....

                60       70       80       90      100
Final Contig Amplicon F      CCGGCTGCGAGGCCGAGGCCGAGGCCAAGGCCATGTACTTCTTCGTGCAG
Sequence NM_001099930.1      .....

                110      120      130      140      150
Final Contig Amplicon F      CAGTTCACCGACATGGAGCAAGGCAAGGTGCTGGAGGCGCTGATACCGCT
Sequence NM_001099930.1      .....

                160      170      180      190      200
Final Contig Amplicon F      CCAGGGCCTGGAGGCGCGCGTGGCGGCCACCGTGGACCTGATCAGCAGCA
Sequence NM_001099930.1      .....

                210      220      230      240      250
Final Contig Amplicon F      GCCACGCGGGCCTGGACCGCCACGCCCTCAGCTTCGCGCTCGCTCCTTC
Sequence NM_001099930.1      .....

                260      270      280      290      300
Final Contig Amplicon F      TACCAGAAGCTGCGCGCCGCCGAGAACTACTGGCCGCAGGCCACCTACCA
Sequence NM_001099930.1      .....

                310      320      330      340      350
Final Contig Amplicon F      CGGCAACGTGACGCTGCTGCGGCCAAGACGGGCGGCGCTACGGCGAGG
Sequence NM_001099930.1      .....

                360      370      380      390      400
Final Contig Amplicon F      ACCTGGGCGCGACTACAACCTGTTCGCAAGTGTGCGACGGCAAGGTCTCG
Sequence NM_001099930.1      .....

                410      420      430      440      450
Final Contig Amplicon F      GTGCACGTCATCGAGGGCGACCACCGCACGCTGCTGGAGGGCAGCGGCCT
Sequence NM_001099930.1      .....

Final Contig Amplicon F      ....
Sequence NM_001099930.1      ....

```